US20220251109A1 - Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof - Google Patents

Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof Download PDF

Info

Publication number
US20220251109A1
US20220251109A1 US17/607,311 US202017607311A US2022251109A1 US 20220251109 A1 US20220251109 A1 US 20220251109A1 US 202017607311 A US202017607311 A US 202017607311A US 2022251109 A1 US2022251109 A1 US 2022251109A1
Authority
US
United States
Prior art keywords
alkyl
halo
alkoxy
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/607,311
Other languages
English (en)
Inventor
Fusheng ZHOU
Lijian CAI
Tao Jiang
Jichen Zhao
Yingtao LIU
Jinzhu ZHAO
Leitao ZHANG
Zhubo LIU
Ling Peng
Wan He
Huabin Yang
Tao Zhang
Qian Ding
Biao Zheng
Qiang Lv
Jiong Lan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfleet Therapeutics Shanghai Inc
Zhejiang Genfleet Therapeutics Co Ltd
Original Assignee
Genfleet Therapeutics Shanghai Inc
Zhejiang Genfleet Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfleet Therapeutics Shanghai Inc, Zhejiang Genfleet Therapeutics Co Ltd filed Critical Genfleet Therapeutics Shanghai Inc
Assigned to GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. reassignment GENFLEET THERAPEUTICS (SHANGHAI) INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LAN, JIONG, LV, QIANG, DING, QIAN, ZHENG, BIAO, LIU, Yingtao, CAI, Lijian, HE, WAN, JIANG, TAO, LIU, Zhubo, PENG, LING, YANG, Huabin, ZHANG, Leitao, ZHANG, TAO, ZHAO, Jichen, ZHAO, Jinzhu, ZHOU, Fusheng
Assigned to ZHEJIANG GENFLEET THERAPEUTICS CO., LTD., GENFLEET THERAPEUTICS (SHANGHAI) INC. reassignment ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. CORRECTIVE ASSIGNMENT TO CORRECT THE CITY OF THE SECOND ASSIGNEE PREVIOUSLY RECORDED AT REEL: 057969 FRAME: 0134. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: LAN, JIONG, LV, QIANG, DING, QIAN, ZHENG, BIAO, LIU, Yingtao, CAI, Lijian, HE, WAN, JIANG, TAO, LIU, Zhubo, PENG, LING, YANG, Huabin, ZHANG, Leitao, ZHANG, TAO, ZHAO, Jichen, ZHAO, Jinzhu, ZHOU, Fusheng
Publication of US20220251109A1 publication Critical patent/US20220251109A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Definitions

  • the present invention relates to the technical field of medicine, in particular, to a oxaazaquinazolin-7 (8H)-one compound, and its use as a selective inhibitor of KRAS gene mutation as well as a pharmaceutical composition prepared therefrom.
  • Lung cancer is the cancer with the highest incidence in the world. The incidence of lung cancer ranks first among all cancers in China. It is also the cancer with the highest incidence and mortality in China. According to data released by the American Cancer Society in 2016, approximately 1.8 million people suffer from lung cancer, and nearly 80% of lung cancers are non-small cell lung cancer (NSCLC).
  • NSCLC non-small cell lung cancer
  • RAS is a group of closely related monomeric globular proteins (21 kDa molecular weight), which have 188-189 amino acids and bind to guanosine diphosphate GDP or guanosine triphosphate GTP.
  • Members of the RAS subfamily include HRAS, KRAS and NRAS.
  • RAS acts as a molecular switch, and when RAS contains bound GDP, it is in a dormant or closed position and is “inactive”. When cells are exposed to certain growth-promoting stimuli, RAS is induced to convert the bound GDP into GTP. When combined with GTP, RAS is “on” and can interact with other downstream target proteins and activate these proteins.
  • RAS protein itself has a very low inherent ability to hydrolyze GTP and restore it to GDP (thus turning itself into a closed state).
  • the exogenous protein GTPase Activated Protein (GAP) is required to restore it to the closed state.
  • GAP GTPase Activated Protein
  • Any mutation in RAS will affect the interaction between RAS and GAP and the ability of the conversion of GTP to GDP. Such mutation will lead to prolonged protein activation time, thereby prolonging cell signaling, which in turn will cause cells to continue to grow and divide. Since such signaling causes cell growth and division, over-activated RAS signaling can eventually lead to cancer.
  • the present invention provides a oxaazaquinazolin-7 (8H)-one compound, as a selective inhibitor of KRAS mutation, which is advantageous for its high activity, high selectivity and low toxic/side effect and the like.
  • the present invention provides a oxaazaquinazolin-7 (8H)-one compound, or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, the compound has a structure as represented by formula (I):
  • R 1 , R 2 are each independently hydrogen, cyano, C 1-3 alkyl, or —C 1-3 alkyl-NR a R b ;
  • R 01 , R 02 , R 03 , R 04 , R 05 , R 06 are each independently hydrogen, C 1-6 alkyl, —C 1-4 alkyl-hydroxy, —C 1-4 alkyl-cyano, —C 1-4 alkyl-C 1-6 alkoxy, —C 1-4 alkyl-halo C 1-6 alkyl, or —C 1-4 alkyl-halo C 1-6 alkoxy;
  • L is a bond, (CR L1 R L2 ) n , C(O), C(O)C(R L1 R L2 ), or C(R L1 R L2 )C(O); wherein R L1 , R L2 are each independently hydrogen, halo, or C 1-6 alkyl;
  • n 1 or 2;
  • X 1 is NR x1 , O, or CR x2 R x3 ; wherein R x1 is hydrogen, or C 1-6 alkyl; R x2 , R x3 are each independently hydrogen, halo, cyano, C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkyl, halo C 1-6 alkoxy, C 3-6 monocyclic cycloalkyl, NR g R h , —C 1-4 alkyl-hydroxy, —C 1-4 alkyl-cyano, —C 1-4 alkyl-C 1-6 alkoxy, —C 1-4 alkyl-halo C 1-6 alkyl, or —C 1-4 alkyl-halo C 1-6 alkoxy;
  • X 2 is N, or CR x4 ; wherein R x4 is hydrogen, halo, cyano, C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkyl, halo C 1-6 alkoxy, C 3-6 monocyclic cycloalkyl, NR g R h , —C 1-4 alkyl-hydroxy, —C 1-4 alkyl-cyano, —C 1-4 alkyl-C 1-6 alkoxy, —C 1-4 alkyl-halo C 1-6 alkyl, or —C 1-4 alkyl-halo C 1-6 alkoxy;
  • R a is hydrogen, halo, cyano, C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkyl, halo C 1-6 alkoxy, C 3-6 monocyclic cycloalkyl, Nine, C 2-4 alkenyl, C 2-4 alkynyl, —C 1-4 alkyl-hydroxy, alkyl-cyano, alkyl-C 1-6 alkoxy, —C 1-4 alkyl-halo C 1-6 alkyl, or —C 1-4 alkyl-halo C 1-6 alkoxy;
  • R b is C 6-10 aryl, or C 5-10 heteroaryl; the C 6-10 aryl, C 5-10 heteroaryl are unsubstituted or substituted by 1, 2, 3, or 4 substituent(s) independently selected from the group S1, the substituents of the group S1 are halo, cyano, nitro, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkyl, halo C 1-6 alkoxy, C 3-6 monocyclic cycloalkyl, NR i R j , C(O)NR e R f , —SO 2 C 1-3 alkyl, —SO 2 halo C 1-3 alkyl, —SO 2 NR e R f , —C 1-4 alkyl-hydroxy, —C 1-4 alkyl-cyano, alkyl-C 1-6 alkoxy, —C 1-4 alkyl-halo C 1-6 alkyl, —C 1-4 alkyl-halo
  • R c is C 1-6 alkyl, C 6-10 aryl, C 5-10 heteroaryl, C 3-6 monocyclic cycloalkyl, C 3-6 monocyclic heterocyclyl, 7- to 11-membered spirocycloalkyl, alkyl-C 6-10 aryl, —C 1-4 alkyl-C 5-10 heteroaryl, —NR e —C 6-10 aryl, —O—C 6-10 aryl, —C 1-4 alkyl-C 3-6 monocyclic heterocyclyl, —C 1-4 alkyl-C 3-6 monocyclic cycloalkyl; wherein
  • the C 3-6 monocyclic cycloalkyl is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexdienyl, cyclobutanone, cyclobutan-1,2-dione, cyclopentanone, cyclopentan-1,3-dione, cyclohexanone, cyclohexan-1,3-dione;
  • the C 3-6 monocyclic heterocyclyl is selected from the group consisting of: aziridine, oxirane, azetidine, azetidin-2-one, oxetane, oxetan-2-one, oxazolidine, pyrrolidin-2-one, pyrrolidin-2,5-dione, 1,3-dioxolane, dihydrofuran-2 (3H)-one, dihydrofuran-2,5-dione, piperidin-2-one, piperidin-2,6-dione, tetrahydro-2H-pyran-2-one, imidazolidine, tetrahydrofuran, tetrahydrothiophene, tetrahydropyrrole, 1,3-dioxolan-2-one, oxazolidin-2-one, imidazolidine-2-one, piperidine, piperazine, piperazin-2-one, morpholine, morpholin-3-one
  • the —C 1-4 alkyl- is unsubstituted or substituted by 1, 2, 3, or 4 substituent(s) independently selected from C 1-3 alkyl;
  • the C 1-6 alkyl, C 6-10 aryl, C 5-10 heteroaryl, 7- to 11-membered spirocycloalkyl, C 3-6 monocyclic cycloalkyl, C 3-6 monocyclic heterocyclyl are unsubstituted or substituted by 1, 2, 3, or 4 substituent(s) independently selected from the group S2, the substituents of the group S2 are halo, cyano, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkyl, halo C 1-6 alkoxy, C 3-6 monocyclic cycloalkyl, C 3-6 monocyclic heterocyclyl, NR i R j , C(O)NR e R f , —SO 2 C 1-3 alkyl, —SO 2 halo C 1-3 alkyl, —SO 2 NR e R f , —C 1-4 alkyl-hydroxy, —C 1-4 alkyl-C 2-4 alky
  • R a , R b , R c , R d , R e , R f , R g , R h are each independently hydrogen, or C 1-3 alkyl;
  • R i , R j are each independently hydrogen, C 1-3 alkyl, —C(O)C 1-3 alkyl, —CO 2 C 1-3 alkyl.
  • the compound of formula (I) has a structure as shown in formula (IA) or formula (IB):
  • the present invention provides an oxaazaquinazolin-7 (8H)-one compound or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, the compound has a structure as represented by formula (II):
  • R b ′ is C 6-10 aryl, C 5-10 heteroaryl, C 3-6 monocyclic heterocyclyl, pyrimidinonyl, or pyridonyl; the C 6-10 aryl, C 5-10 heteroaryl, C 3-6 monocyclic heterocyclyl, pyrimidinonyl, and pyridonyl are unsubstituted or substituted by 1, 2, 3, or 4 substituent(s) independently selected from the group S1, or substituted by 1, 2, 3, or 4 substituent(s) independently selected from deuterated C 1-6 alkyl and deuterated C 1-6 alkoxy; the substituents of the group S1 are halo, cyano, nitro, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkyl, halo C 1-6 alkoxy, C 3-6 monocyclic cycloalkyl, NR i R j , C(O)NR e R f , —SO 2 C 1-3 al
  • R c ′ is C 1-6 alkyl, C 6-10 aryl, C 5-10 heteroaryl, C 3-6 monocyclic cycloalkyl, C 3-6 monocyclic heterocyclyl, 7- to 11-membered spirocycloalkyl, —C 1-4 alkyl-C 6-10 aryl, —C 1-4 alkyl-C 5-10 heteroaryl, —NR e —C 6-10 aryl, —O—C 6-10 aryl, —C 1-4 alkyl-C 3-6 monocyclic heterocyclyl, —C 1-4 alkyl-C 3-6 monocyclic cycloalkyl, pyrimidinonyl, or pyridonyl;
  • the C 3-6 monocyclic cycloalkyl is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexdienyl, cyclobutanone, cyclobutan-1,2-dione, cyclopentanone, cyclopentan-1,3-dione, cyclohexanone, cyclohexan-1,3-dione;
  • the C 3-6 monocyclic heterocyclyl is selected from the group consisting of: aziridine, oxirane, azetidine, azetidin-2-one, oxetane, oxetan-2-one, oxazolidine, pyrrolidin-2-one, pyrrolidin-2,5-dione, 1,3-dioxolane, dihydrofuran-2 (3H)-one, dihydrofuran-2,5-dione, piperidin-2-one, piperidin-2,6-dione, tetrahydro-2H-pyran-2-one, imidazolidine, tetrahydrofuran, tetrahydrothiophene, tetrahydropyrrole, 1,3-dioxolan-2-one, oxazolidin-2-one, imidazolidine-2-one, piperidine, piperazine, piperazin-2-one, morpholine, morpholin-3-one
  • the —C 1-4 alkyl- is unsubstituted or substituted by 1, 2, 3, or 4 substituent(s) independently selected from C 1-3 alkyl;
  • the C 1-6 alkyl, C 6-10 aryl, C 5-10 heteroaryl, 7- to 11-membered spirocycloalkyl, C 3-6 monocyclic cycloalkyl, C 3-6 monocyclic heterocyclyl, pyrimidinonyl, and pyridonyl are unsubstituted or substituted by 1, 2, 3, or 4 substituent(s) independently selected from the group S2, or substituted by 1, 2, 3, or 4 substituent(s) independently selected from deuterated C 1-6 alkyl and deuterated C 1-6 alkoxy;
  • the substituents of the group S2 are halo, cyano, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkyl, halo C 1-6 alkoxy, C 3-6 monocyclic cycloalkyl, C 3-6 monocyclic heterocyclyl, NR i R j , C(O)NR e R f , —SO 2 C 1-3 al
  • R e , R f are each independently hydrogen, or C 1-3 alkyl
  • R i , R j are each independently hydrogen, C 1-3 alkyl, —C(O)C 1-3 alkyl, —CO 2 C 1-3 alkyl;
  • R 1 , R 2 , R 01 , R 02 , R 03 , R 04 , R 05 , R 06 , L, X 1 , X 2 , R a are as defined above.
  • the compound of formula (II) has a structure as shown in formula (IIA) or formula (IIB):
  • pyridonyl in R b ′ is pyridinyl-2 (1H)-one.
  • pyrimidinonyl in R b ′ is pyrimidinyl-4 (3H)-one.
  • the substituents of the group S1 are halo, cyano, nitro, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, halo C 1-3 alkyl, halo C 1-3 alkoxy, C 3-6 monocyclic cycloalkyl, NR i R j , —C(O)NR e R f , —SO 2 C 1-3 alkyl, —SO 2 halo C 1-3 alkyl, —SO 2 NR e R f , —C 1-2 alkyl-hydroxy, —C 1-2 alkyl-cyano, —C 1-2 alkyl-C 1-3 alkoxy, —C 1-2 alkyl-halo C 1-3 alkyl, —C 1-2 alkyl-halo C 1-3 alkoxy, —C 1-2 alkyl-C 3-6 monocyclic heterocyclyl, —C 1-2 alkyl-NR e R f , —C
  • the substituents of the group S1 are halo, cyano, nitro, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, halo C 1-3 alkyl, halo C 1-3 alkoxy, C 3-6 monocyclic cycloalkyl, NR i R j , —C(O)NR e R f , —SO 2 C 1-3 alkyl, —SO 2 halo C 1-3 alkyl, —SO 2 NR e R f , —CH 2 -hydroxy, —CH 2 -cyano, —CH 2 —C 1-3 alkoxy, —CH 2 -halo C 1-3 alkyl, —CH 2 -halo C 1-3 alkoxy, —CH 2 —C 3-6 monocyclic heterocyclyl, —CH 2 —NR e R f , —CH 2 —C(O)NR e R f , —CH 2 —CH 2 —C —
  • the substituents of the group S1 are halo, cyano, nitro, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, halo C 1-3 alkyl, halo C 1-3 alkoxy, C 3-6 monocyclic cycloalkyl, NR i R j , —C(O)NR e R f , —CH 2 -hydroxy, —CH 2 -cyano; wherein R i is hydrogen, —C(O)CH 3 , or —CO 2 CH 3 ; R e , R f , R j are each independently hydrogen, or C 1-3 alkyl.
  • the substituents of the group S2 are halo, cyano, hydroxy, C 1-6 alkyl, C 1-3 alkoxy, halo C 1-3 alkyl, halo C 1-3 alkoxy, C 3-6 monocyclic cycloalkyl, C 3-6 monocyclic heterocyclyl, amino, NHCH 3 , N(CH 3 ) 2 , C(O)NR e R f , —SO 2 C 1-3 alkyl, —SO 2 halo C 1-3 alkyl, —SO 2 NR e R f , —C 1-2 alkyl-hydroxy, —C 1-2 alkyl-ethynyl, —C 1-2 alkyl-cyano, —C 1-2 alkyl-C 1-3 alkoxy, —C 1-2 alkyl-halo C 1-3 alkyl, —C 1-2 alkyl-halo C 1-3 alkyl, —C 1-2 alkyl-halo C 1-3 alkyl
  • the substituents of the group S2 are halo, cyano, hydroxy, C 1-4 alkyl, C 1-3 alkoxy, halo C 1-3 alkyl, halo C 1-3 alkoxy, C 3-6 monocyclic cycloalkyl, C 3-6 monocyclic heterocyclyl, amino, NHCH 3 , N(CH 3 ) 2 , C(O)NR e R f , —SO 2 C 1-3 alkyl, —SO 2 halo C 1-3 alkyl, —SO 2 NR e R f , —CH 2 -hydroxy, —CH 2 -ethynyl, —CH 2 -cyano, —CH 2 —C 1-3 alkoxy, —CH 2 -halo C 1-3 alkyl, —CH 2 -halo C 1-3 alkoxy, —CH 2 —C 3-6 monocyclic heterocyclyl, —CH 2 —C 3-6 monocyclic heterocyclyl,
  • the substituents of the group S2 are halo, cyano, hydroxy, C 1-4 alkyl, C 1-3 alkoxy, halo C 1-3 alkyl, C 3-6 monocyclic cycloalkyl, C 3-6 monocyclic heterocyclyl, amino, NHCH 3 , N(CH 3 ) 2 , —CH 2 -hydroxy, —CH 2 -ethynyl; wherein the C 3-6 monocyclic cycloalkyl in the substituents of the group S2 is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; the C 3-6 monocyclic heterocyclyl is selected from the group consisting of: aziridine, oxirane, azetidine, oxetane, tetrahydrofuran, tetrahydrothiophene, tetrahydropyrrole, piperidine,
  • the C 3-6 monocyclic cycloalkyl in the substituents of the group S1 is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexdienyl, cyclobutanone, cyclobutan-1,2-dione, cyclopentanone, cyclopentan-1,3-dione, cyclohexanone, cyclohexan-1,3-dione.
  • the C 3-6 monocyclic heterocyclyl in the substituents of the group S1 is selected from the group consisting of: aziridine, oxirane, azetidine, azetidin-2-one, oxetane, oxetan-2-one, oxazolidine, pyrrolidin-2-one, pyrrolidin-2,5-dione, 1,3-dioxolane, dihydrofuran-2 (3H)-one, dihydrofuran-2,5-dione, piperidin-2-one, piperidin-2,6-dione, tetrahydro-2H-pyran-2-one, imidazolidine, tetrahydrofuran, tetrahydrothiophene, tetrahydropyrrole, 1,3-dioxolan-2-one, oxazolidin-2-one, imidazolidine-2-one, piperidine, piperazine, pipe
  • the C 3-6 monocyclic cycloalkyl in the substituents of the group S2 is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • the C 3-6 monocyclic heterocyclyl in the substituents of the group S2 is selected from the group consisting of: aziridine, oxirane, azetidine, oxetane, tetrahydrofuran, tetrahydrothiophene, tetrahydropyrrole, piperidine, piperazine, morpholine, thiomorpholine, thiomorpholine-1,1-dioxide, tetrahydropyran.
  • R 1 , R 2 are each independently hydrogen, cyano, C 1-3 alkyl, —CH 2 NH 2 , —CH 2 NHCH 3 , or —CH 2 N(CH 3 ) 2 .
  • R 1 is hydrogen;
  • R 2 is hydrogen, cyano, C 1-3 alkyl, —CH 2 NH 2 , —CH 2 NHCH 3 , or —CH 2 N(CH 3 ) 2 .
  • R 1 , R 2 are hydrogen.
  • R 01 , R 02 , R 03 , R 04 , R 05 , R 06 are each independently hydrogen, C 1-3 alkyl, —C 1-2 alkyl-hydroxy, —C 1-2 alkyl-cyano, —C 1-2 alkyl-C 1-3 alkoxy, —C 1-2 alkyl-halo C 1-3 alkyl, —C 1-2 alkyl-halo C 1-3 alkoxy;
  • R 01 , R 02 , R 03 , R 04 , R 05 , R 06 are each independently hydrogen, C 1-3 alkyl, —CH 2 -hydroxy, —CH 2 -cyano, —CH 2 —C 1-3 alkoxy, —CH 2 -halo C 1-3 alkyl, —CH 2 -halo C 1-3 alkoxy;
  • R 05 , R 06 are hydrogen;
  • R 01 , R 02 , R 03 , R 04 are each independently hydrogen, C 1-3 alkyl, —CH 2 -hydroxy, —CH 2 -cyano, —CH 2 —C 1-3 alkoxy, —CH 2 -halo C 1-3 alkyl, —CH 2 -halo C 1-3 alkoxy;
  • R 01 , R 02 together with the carbon atom attached thereto formed C 3-6 monocyclic cycloalkyl is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexdienyl, cyclobutanone, cyclobutan-1,2-dione, cyclopentanone, cyclopentan-1,3-dione, cyclohexanone, cyclohexan-1,3-dione.
  • R 03 , R 04 together with the carbon atom attached thereto formed C 3-6 monocyclic cycloalkyl is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexdienyl, cyclobutanone, cyclobutan-1,2-dione, cyclopentanone, cyclopentan-1,3-dione, cyclohexanone, cyclohexan-1,3-dione.
  • R 05 , R 06 together with the carbon atom attached thereto formed C 3-6 monocyclic cycloalkyl is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexdienyl, cyclobutanone, cyclobutan-1,2-dione, cyclopentanone, cyclopentan-1,3-dione, cyclohexanone, cyclohexan-1,3-dione.
  • R 02 , R 04 are each independently hydrogen, C 1-3 alkyl, —CH 2 -hydroxy, —CH 2 -cyano, —CH 2 —C 1-3 alkoxy, —CH 2 -halo C 1-3 alkyl, —CH 2 -halo C 1-3 alkoxy;
  • R 01 , R 03 , R 05 , R 06 are hydrogen.
  • R 02 , R 04 are each independently hydrogen, CH 3 , —CH 2 -hydroxy, or —CH 2 -cyano; R 01 , R 03 , R 05 , R 06 are hydrogen.
  • R 02 , R 04 are each independently hydrogen, or CH 3 ;
  • R 01 , R 03 , R 05 , R 06 are hydrogen.
  • R 01 , R 02 , R 03 , R 04 , R 05 , R 06 are hydrogen.
  • L is a bond, or (CR L1 R L2 ) n ; wherein R L1 , R L2 are each independently hydrogen, halo, or C 1-6 alkyl; n is 1 or 2.
  • L is a bond, or (CR L1 R L2 ) n ; wherein R L1 , R L2 are each independently hydrogen, halo, or C 1-3 alkyl; n is 1 or 2.
  • L is a bond, or (CH 2 ) n ; n is 1 or 2.
  • L is (CR L1 R L2 ) n ; wherein R L1 , R L2 are each independently hydrogen, halo, or C 1-3 alkyl; n is 1 or 2.
  • L is CH 2 or CH 2 CH 2 .
  • L is CH 2 .
  • X 1 is NR x1 or O; wherein R x1 is hydrogen, or C 1-6 alkyl.
  • X 1 is NR x1 or O; wherein R x1 is hydrogen, or C 1-3 alkyl.
  • X 1 is O.
  • L is CH 2 ; X 1 is O.
  • L is CH 2 CH 2 ; X 1 is O.
  • X 2 is N or CR x4 ; wherein R x4 is hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy, or halo C 1-6 alkyl.
  • X 2 is N or CR x4 ; wherein R x4 is hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, or halo C 1-3 alkyl.
  • X 2 is N.
  • X 2 is CR x4 ; wherein R x4 is hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, or halo C 1-3 alkyl.
  • X 2 is CR x4 ; wherein R x4 is hydrogen, fluorine, chlorine, C 1-4 alkyl.
  • R a is hydrogen, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, halo C 1-3 alkyl, halo C 1-3 alkoxy, C 3-6 monocyclic cycloalkyl, NR c R d , C 2-4 alkenyl, C 2-4 alkynyl, —C 1-2 alkyl-hydroxy, —C 1-2 alkyl-cyano, —C 1-2 alkyl-C 1-3 alkoxy, —C 1-2 alkyl-halo C 1-3 alkyl, or —C 1-2 alkyl-halo C 1-3 alkoxy; wherein R c , R d are each independently hydrogen, or C 1-3 alkyl.
  • R a is hydrogen, halo, cyano, C 1-3 alkyl, C 1-3 alkoxy, halo C 1-3 alkyl, halo C 1-3 alkoxy, C 3-6 monocyclic cycloalkyl, NR c R d , vinyl, ethynyl, —CH 2 -hydroxy, —CH 2 -cyano, —CH 2 —C 1-3 alkoxy, —CH 2 -halo C 1-3 alkyl, or —CH 2 -halo C 1-3 alkoxy; wherein R c , R d are each independently hydrogen, or C 1-3 alkyl.
  • the C 3-6 monocyclic cycloalkyl in R a is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • R a is hydrogen, halo, cyano, C 1-3 alkyl, C 1-3 alkoxy, halo C 1-3 alkyl, NR c R d , ethynyl, —CH 2 -hydroxy, —CH 2 —C 1-3 alkoxy; wherein R c , R d are each independently hydrogen, or C 1-3 alkyl.
  • R a is hydrogen, halo, cyano, C 1-3 alkyl, C 1-3 alkoxy, halo C 1-3 alkyl, amino, NHCH 3 , N(CH 3 ) 2 , ethynyl, —CH 2 -hydroxy, or —CH 2 —C 1-3 alkoxy.
  • R a is hydrogen, halo, cyano, or C 1-3 alkyl.
  • R a is hydrogen, fluorine, chlorine, cyano, methyl, ethyl, propyl, or isopropyl.
  • the 7- to 11-membered spirocycloalkyl in R c , R c ′ is a monospirocycloalkyl containing one spiro atom formed by any two monocyclic cycloalkyl rings selected from cyclopropyl ring, cyclobutyl ring, cyclopentyl ring, and cyclohexyl ring.
  • the C 6-10 aryl in R b , R c , R b ′, R c ′ are each independently phenyl, naphthyl, a 9- or 10-membered aromatic fused bicyclic ring formed by fusing a phenyl to one C 5-6 monocyclic heterocyclyl, or a 9- or 10-membered aromatic fused bicyclic ring formed by fusing a phenyl to one C 5-6 monocyclic cycloalkyl.
  • the C 5-6 monocyclic heterocyclyl in the 9- or 10-membered aromatic fused bicyclic ring formed by fusing a phenyl to one C 5-6 monocyclic heterocyclyl is selected from the group consisting of: oxazolidine, pyrrolidin-2-one, pyrrolidin-2,5-dione, 1,3-dioxolane, dihydrofuran-2 (3H)-one, dihydrofuran-2,5-dione, piperidin-2-one, piperidin-2,6-dione, tetrahydro-2H-pyran-2-one, imidazolidine, tetrahydrofuran, tetrahydrothiophene, tetrahydropyrrole, 1,3-dioxolan-2-one, oxazolidin-2-one, imidazolidine-2-one, piperidine, piperazine, piperazin-2-one, morpholine, morph
  • the C 5-6 monocyclic cycloalkyl in the 9- or 10-membered aromatic fused bicyclic ring formed by fusing a phenyl to one C 5-6 monocyclic cycloalkyl is selected from the group consisting of: cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexdienyl, cyclopentanone, cyclopentan-1,3-dione, cyclohexanone, cyclohexan-1,3-dione.
  • the C 5-10 heteroaryl in R b , R c , R b ′, R c ′ are each independently a 5- or 6-membered monoheteroaryl, a 9- or 10-membered biheteroaryl formed by fusing a phenyl to a 5- or 6-membered monoheteroaryl, a 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to a 5- or 6-membered monoheteroaryl, a 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to one C 5-6 monocyclic heterocyclyl, or a 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to one C 5-6 monocyclic cycloalkyl.
  • the C 5-10 heteroaryl in R b , R c , R b ′, R c ′ are a 5- or 6-membered monoheteroaryl
  • the 5- or 6-membered monoheteroaryl are each independently selected from the group consisting of: thiophene, N-alkylcyclopyrrole, furan, thiazole, isothiazole, imidazole, oxazole, pyrrole, pyrazole, triazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, tetrazole, isoxazole, oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, or pyrazine
  • the C 5-10 heteroaryl in R b , R c , R b ′, R c ′ are a 5- or 6-membered monoheteroaryl
  • the 5- or 6-membered monoheteroaryl are each independently has a structure selected from the group consisting of:
  • the 5- or 6-membered monoheteroaryl in the 9- or 10-membered biheteroaryl formed by fusing a phenyl to a 5- or 6-membered monoheteroaryl is selected from the group consisting of: thiophene, N-alkylcyclopyrrole, furan, thiazole, isothiazole, imidazole, oxazole, pyrrole, pyrazole, triazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, tetrazole, isoxazole, oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, or pyrazine.
  • the 5- or 6-membered monoheteroaryl in the 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to one C 5-6 monocyclic heterocyclyl is selected from the group consisting of: thiophene, N-alkylcyclopyrrole, furan, thiazole, isothiazole, imidazole, oxazole, pyrrole, pyrazole, triazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, tetrazole, isoxazole, oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, or pyrazine;
  • the C 5-6 monocyclic heterocyclyl is selected from the group consisting of: oxazolidine, pyrrolidin-2-one, pyrrolidin-2,5-dione, 1,3-dioxolane, dihydrofuran-2 (3H)-one, dihydrofuran-2,5-dione, piperidin-2-one, piperidin-2,6-dione, tetrahydro-2H-pyran-2-one, imidazolidine, tetrahydrofuran, tetrahydrothiophene, tetrahydropyrrole, 1,3-dioxolan-2-one, oxazolidin-2-one, imidazolidine-2-one, piperidine, piperazine, piperazin-2-one, morpholine, morpholin-3-one, morpholin-2-one, thiomorpholin-3-one 1,1-dioxide, thiomorpholine, thiomorpholine-1,1-di
  • the 5- or 6-membered monoheteroaryl in the 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to one C5-6 monocyclic cycloalkyl is selected from the group consisting of: thiophene, N-alkylcyclopyrrole, furan, thiazole, isothiazole, imidazole, oxazole, pyrrole, pyrazole, triazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, tetrazole, isoxazole, oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, or pyrazine
  • the C 5-6 monocyclic cycloalkyl is selected from the group consisting of: cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexdienyl, cyclopentanone, cyclopentan-1,3-dione, cyclohexanone, cyclohexan-1,3-dione.
  • the 9- or 10-membered biheteroaryl has a structure as shown in formula (a) or formula (b):
  • C ring is a 5- or 6-membered monoheteroaryl; wherein the 5- or 6-membered monoheteroaryl is selected from the group consisting of: thiophene, N-alkylcyclopyrrole, furan, thiazole, isothiazole, imidazole, oxazole, pyrrole, pyrazole, triazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, tetrazole, isoxazole, oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, or pyrazine.
  • the C ring has a structure selected from the group consisting of:
  • the 9- or 10-membered biheteroaryl formed by fusing a phenyl to a 5- or 6-membered monoheteroaryl is selected from the group consisting of: benzoxazole, benzisoxazole, benzimidazole, benzothiazole, benzisothiazole, benzotriazole, benzofuran, benzothiophene, indole, indazole, isoindole, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline.
  • the 9- or 10-membered biheteroaryl formed by fusing a phenyl to a 5- or 6-membered monoheteroaryl is selected from the group consisting of: benzo[d]isoxazole, 1H-indole, isoindole, 1H-benzo[d]imidazole, benzo[d]isothiazole, 1H-benzo[d][1,2,3]triazole, benzo[d]oxazole, benzo[d]thiazole, indazole, benzofuran, benzo[b]thiophene, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline.
  • the 8- to 10-membered biheteroaryl has a structure as shown in formula (d) or formula (e):
  • D ring, E ring are a 5- or 6-membered monoheteroaryl; wherein the 5- or 6-membered monoheteroaryl is selected from the group consisting of: thiophene, N-alkylcyclopyrrole, furan, thiazole, isothiazole, imidazole, oxazole, pyrrole, pyrazole, triazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, tetrazole, isoxazole, oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, or pyrazine.
  • the D ring, E ring have a structure each independently selected from the group consisting of:
  • the 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to a 5- or 6-membered monoheteroaryl is selected from the group consisting of: pyridopyrimidine and naphthyridine.
  • the 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to a 5- or 6-membered monoheteroaryl is selected from the group consisting of: pyrido[3,2-d]pyrimidine, pyrido[2,3-d]pyrimidine, pyrido[3,4-d]pyrimidine, pyrido[4,3-d]pyrimidine, 1,8-naphthyridine, 1,7-naphthyridine, 1,6-naphthyridine, 1,5-naphthyridine.
  • the 9- or 10-membered aromatic fused bicyclic ring formed by fusing a phenyl to one C 5-6 monocyclic heterocyclyl has a structure selected from the group consisting of:
  • R b , R b ′ are independently phenyl, naphthyl, a 9- or 10-membered aromatic fused bicyclic ring formed by fusing a phenyl to one C 5-6 monocyclic heterocyclyl, a 5- or 6-membered monoheteroaryl, a 9- or 10-membered biheteroaryl formed by fusing a phenyl to a 5- or 6-membered monoheteroaryl, a 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to a 5- or 6-membered monoheteroaryl; the phenyl, naphthyl, 9- or 10-membered aromatic fused bicyclic ring, 5- or 6-membered monoheteroaryl, 9- or 10-membered biheteroaryl, 8- to 10-membered biheteroaryl are unsubstituted or
  • R b , R b ′ are independently phenyl, or a 9- or 10-membered biheteroaryl formed by fusing a phenyl to a 5- or 6-membered monoheteroaryl; the phenyl, 9- or 10-membered biheteroaryl are unsubstituted or substituted by 1, 2, 3, or 4 substituent(s) independently selected from the group S1.
  • R b , R b ′ are independently phenyl, or a 9-membered biheteroaryl formed by fusing a phenyl to a 5-membered monoheteroaryl; the phenyl, 9-membered biheteroaryl are unsubstituted or substituted by 1, 2, 3, or 4 substituent(s) independently selected from the group S1.
  • R b , R b ′ are independently phenyl
  • R b , R b ′ have a structure selected from the group consisting of:
  • R s1 , R s2 are each independently selected from the substituent of group S1.
  • the 9- or 10-membered biheteroaryl formed by fusing a phenyl to a 5- or 6-membered monoheteroaryl has a structure selected from the group consisting of:
  • the 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to a 5- or 6-membered monoheteroaryl has a structure selected from the group consisting
  • the 9- or 10-membered biheteroaryl formed by fusing a phenyl to a 5- or 6-membered monoheteroaryl has a structure selected from the group consisting of:
  • the 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to a 5- or 6-membered monoheteroaryl has a structure selected from the group consisting of:
  • the 9- or 10-membered biheteroaryl formed by fusing a phenyl to a 5- or 6-membered monoheteroaryl or the 8- to 10-membered biheteroaryl formed by fusing a 5- or 6-membered monoheteroaryl to a 5- or 6-membered monoheteroaryl has a structure selected from the group consisting of:
  • the 9- or 10-membered aromatic fused bicyclic ring formed by fusing a phenyl to one C 5-6 monocyclic heterocyclyl has a structure selected from the group consisting of:
  • R b , R b ′ have a structure independently selected from the group consisting of:
  • R b , R b ′ have a structure each independently selected from the group consisting of:
  • R c , R c ′ have a structure independently selected from the group consisting of:
  • R c , R c ′ have a structure each independently selected from the group consisting of:
  • the R 1 , R 2 , R 01 , R 02 , R 03 , R 04 , R 05 , R 06 , L, X 1 , X 2 , R a , R b , R c , R b ′, R c ′ are each independently the corresponding groups in respective specific compounds in the Examples.
  • the C 3-6 cycloalkyl in any group is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • the 3- to 6-membered heterocycloalkyl in any group is selected from the group consisting of: aziridine, oxirane, azetidine, oxetane, tetrahydrofuran, tetrahydrothiophene, tetrahydropyrrole, piperidine, piperazine, morpholine, thiomorpholine, thiomorpholine-1,1-dioxide, tetrahydropyran.
  • the 5- or 6-membered monocycloheteroaryl is selected from the group consisting of: thiophene, N-alkylcyclopyrrole, furan, thiazole, isothiazole, imidazole, oxazole, pyrrole, pyrazole, triazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, tetrazole, isoxazole, oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine.
  • the 8- to 10-membered bicycloheteroaryl in any group is selected from the group consisting of: benzoxazole, benzisoxazole, benzimidazole, benzothiazole, benzisothiazole, benzotriazole, benzofuran, benzothiophene, indole, indazole, isoindole, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, pyridopyrimidine, naphthyridine.
  • the compound of formula (I) is selected from the group consisting of respective specific compounds as noted in the Examples, especially, any compound of Z1 to Z14.
  • the compound of formula (I) is selected from the group consisting of the compounds as prepared in the Examples of the present application.
  • the compound of formula (I) is selected from the Table A-1.
  • the compound of formula (I) is selected from the Table A-2.
  • the representative compounds of formula (I) and formula (II) include the compounds listed in Table A-1 below, or pharmaceutically acceptable salts, stereoisomers, solvents or prodrugs thereof:
  • the representative compounds of formula (I) and formula (II) include the compounds listed in Table A-2 below, or pharmaceutically acceptable salts, stereoisomers, solvents or prodrugs thereof:
  • the present invention provides a pharmaceutical composition, comprising the compound as described above or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof; and a pharmaceutically acceptable carrier.
  • the term “pharmaceutically acceptable carrier” means any formulation or carrier medium capable of delivering an effective amount of the active substance of the invention without interfering with the biological activity of the active substance and without causing adverse effects to the host or subject. It is a non-toxic, inert, solid, semi-solid substance or liquid filling agent, diluent, packaging material or auxiliary preparation or any type of excipient.
  • Representative carriers include water, oil, vegetables and minerals, cream base, lotion base, ointment base and the like. These bases include suspension agents, viscosifiers, transdermal promoters and the like. Their formulations are known to those skilled in the field of cosmetic or topical medicine.
  • the pharmaceutical composition may be administered in any form of oral, spray inhalation, rectal administration, nasal administration, buccal administration, topical administration, parenteral administration, such as, subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal and intracranial injection or infusion, or administered by means of an explanted reservoir.
  • the compound of the present invention may be formulated into any orally acceptable dosage form, including but not limited to tablets, capsules, aqueous solutions or aqueous suspensions.
  • Carriers used in tablets typically include lactose and cornstarch.
  • Lubricants such as magnesium stearate may also be added.
  • Diluents used in capsules typically include lactose and dried cornstarch.
  • Aqueous suspensions are typically formulated by mixing an active ingredient with appropriate emulsifiers and suspension agents. Sweeteners, fragrances or colorants may be added to the oral dosage form as required.
  • the compound of the present invention When topically administered, especially to the affected surface or organ readily accessible by topical application, such as eye, skin, or lower intestinal neuropathy, the compound of the present invention may be formulated into different topical dosage forms depending on the surface or organs.
  • the compound of the present invention may be formulated into a dosage form of micronized suspension or solution using an isotonic sterile saline of a certain pH as the carrier, in which preservatives such as benzyl alkoxide chloride may or may not be added.
  • the compound may be formulated into a form of cream, such as, Vaseline cream.
  • the compound of the present invention When administered topically to skin, the compound of the present invention may be formulated into a suitable dosage form of ointment, lotion or cream, in which an active ingredient is suspended or dissolved in one or more carriers.
  • the carriers useful in an ointment formulation include but not limited to: mineral oils, liquid vaseline, white vaseline, propylene glycol, polyoxyethylene, polypropylene oxide, emulsified wax and water.
  • the carriers useful in a lotion or cream include but not limited to: mineral oils, sorbitan monostearate, Tween 60, Cetyl ester wax, hexadecenyl aryl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the compound of the present invention may be administered in a dosage form of sterile injections, including sterial aqueous injection or oil suspension or sterile injection solution.
  • Useful carriers and solvents include water, Ringer's solution and isotonic sodium chloride solution.
  • sterilized non-volatile oils can also be used as solvents or suspension media, such as monotriglycerides or diglycerides.
  • the present invention provides use of the above oxaazaquinazolin-7 (8H)-one compound, or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof in the preparation of a medicament for preventing and/or treating cancer.
  • the cancer is pancreatic ductal cancer, colorectal cancer, multiple myeloma, lung cancer, skin melanoma, endometrioid carcinoma, uterine carcinosarcoma, thyroid cancer, acute myeloid leukemia, bladder urothelial cancer, stomach cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, lung squamous cell carcinoma, small cell lung cancer, renal papillary cell carcinoma, adenoid cystic carcinoma, chromophobe renal cell carcinoma, liver cancer, breast invasive carcinoma, cervical squamous cell carcinoma, ovarian serous adenocarcinoma, adrenal cortex carcinoma, prostate cancer, neuroblastoma, brain low-grade glioma, glue Plasmoblastoma, medulloblastoma, esophageal squamous cell carcinoma, renal clear cell
  • the cancer is lung cancer, preferably non-small cell lung cancer.
  • the present invention provides use of the above oxaazaquinazolin-7 (8H)-one compound, or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof in the preparation of an inhibitor of KRAS mutation (preferably, the KRAS mutation is KRAS G12C mutation).
  • the present invention provides a method for treating cancer, comprising the step of administering to a patient in need thereof a therapeutically effective amount of compound, or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, or any combination thereof, or the above pharmaceutical composition.
  • the term “subject” refers to an aminal, especially a mammal, preferably a human being.
  • the term “effective amount” or “therapeutically effective amount” refers to the sufficient amount of a drug or agent that is non-toxic but has the desired effect.
  • the amount of a given drug depends on a number of factors, such as the particular dosage regimen, the type of disease or disorder and its severity, and the uniqueness of the subject or the host in need of treatment (e.g., body weight), however, depending on the particular circumstances, including, for example, the particular drug that has been employed, the route of administration, the condition being treated, and the subject or host being treated, the dosage administered can be decided by methods routinely known in the art.
  • the dosage administered will typically range from 0.02 to 5000 mg/day, for example from about 1 to 1500 mg/day.
  • the desired dose may conveniently be presented as a single dose, or concurrently (or in a short period of time) or in divided doses at appropriate intervals, such as two, three, four or more divided doses per day. It will be understood by those skilled in the art that although the above dosage ranges are given, the specific effective amount can be appropriately adjusted depending on the condition of the patient and in connection with the diagnosis of the physician.
  • the term “pharmaceutically acceptable salts” refers to salts of the compound of the present invention which are pharmaceutically acceptable, and can retain the biological effectiveness of the free base without other side effects.
  • the type of pharmaceutical acceptable salts includes: acid addition salts formed with inorganic acids (such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like) or organic acids (such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, trifluoroacetic acid, formic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, naphthalene sulfonic acid, camphor
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing acid radicals or base radicals by conventional chemical methods.
  • such salts are prepared by the reaction of these compounds in a form of free acid or base with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of the both.
  • non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.
  • the compounds provided herein also exist in prodrug forms.
  • the prodrugs of the compounds described herein are readily chemically altered under physiological conditions to be converted into the compounds of the invention.
  • prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an in vivo environment.
  • solvate refers to a substance formed by combining the compound of the invention with a pharmaceutically acceptable solvent.
  • Pharmaceutical acceptable solvates include water, ethanol, acetic acid and the like.
  • the solvates include stoichiometric solvates and non-stoichiometric solvates, preferably hydrates.
  • Certain compounds of the present invention may be present in unsolvated or solvated forms, including hydrated forms. In general, solvated forms are equivalent to unsolvated forms and both are included within the scope of the present invention.
  • the compound as represented by formula (I) or formula (II) of the present invention may contain one or more chiral centers and exist in different optically active forms.
  • the compound may contain enantiomers.
  • the present invention includes these two isomers and mixtures of isomers, such as racemic mixtures. Enantiomers can be resolved by methods known in the art, such as crystallization and chiral chromatography and other methods.
  • diastereomers may exist.
  • the present invention includes resolved optically pure specific isomers and mixtures of diastereomers.
  • Diastereomers can be resolved by methods known in the art, such as crystallization and preparative chromatography.
  • the term “stereoisomers” include both conformational and configurational isomers, wherein configurational isomers mainly include cis-trans isomers and optical isomers.
  • the compound of the present invention may be present in a stereoisomeric form, and thereby cover all possible stereoisomeric forms, including but not limited to cis-trans isomers, tautomers, enantiomers, diastereomers, atropisomers, and the like.
  • the compound of the present invention can also be present in forms such as any combination or any mixture of the aforementioned stereoisomers, such as a mixture of mesoisomer, racemate, atropisomer in equal amounts, and the like.
  • the compound of the invention contains an olefinic double bond, it includes a cis-isomer and trans-isomer, and any combination thereof, unless otherwise specified.
  • the atropisomers of the present invention are stereoisomers with axial or planar chirality based on the restriction of intramolecular rotation.
  • the compound of the present invention have two atropisomers derived from axial asymmetry, which is produced by restricting the rotation of bond when the substituents R b or R c , R b ′ or R c ′ are cyclic groups such as C 6-10 aryl, a 5- or 6-membered monocycloheteroaryl, a 8- to 10-membered bicyclo heteroaryl or pyridonyl (especially when the adjacent positions of two ends of the bond have substituents at the ortho positions) connected to the rings such as substituted naphthalidone, and forming a steric hindrance.
  • R b or R c , R b ′ or R c ′ are cyclic groups such as C 6-10 aryl, a 5- or 6-membered monocycloheteroaryl, a 8- to 10-membered bicyclo heteroaryl or pyridonyl (especially when the adjacent positions of two ends of the bond have substituents at the ortho positions
  • the compound has a structure of formula (I) or formula (II), or the compound of formula (I) or formula (II) has an isomer produced by asymmetric carbon, and the like, it represents any one of a pair of atropisomers present in each isomeric compound. And as a medicine, an atropisomer with excellent activity is preferred.
  • the compound of formula (I) or formula (II) has optical isomers derived from asymmetric carbon, axial asymmetry, and the like, if necessary, a single isomer can be obtained by methods known in the art, such as crystallization or chromatography (e.g., chiral chromatography) and other methods.
  • the atropisomers of the compound of the present invention can be expressed in P or M configuration, and can also be labeled in other commonly used ways known in the art.
  • the present invention provides compounds shown in the above-mentioned various structures, or tautomers, cis-trans isomers, mesoisomers, racemates, enantiomers, diastereomers, atropisomers thereof, or the form of a mixture thereof, wherein “the form of a mixture thereof” includes any of the aforementioned stereoisomers (e.g., tautomers, cis-trans isomers, enantiomers, diastereomers, atropisomers) and/or mixtures (mesoisomers, racemates) in any form, such as mixtures of cis-trans isomers, mixtures of enantiomers and diastereomers, mixtures of diastereomers, mixtures of atropisomers, or mixtures of cis-trans isomers and racemates, mixtures of enantiomers and diastereomers, mixtures of atropisomers and diastereomers mixtures, and the like.
  • alkyl refers to a liner or branched aliphatic hydrocarbon group having 1 to 20 carbon atoms.
  • C 1-10 alkyl refers to a liner or branched alkyl group having 1 to 10 carbon atoms, more preferably 1, 2, 3, 4, 5 or 6 carbon atoms, i.e., C 1-6 alkyl, more preferably, C 1-4 alkyl, the most preferably, C 1-3 alkyl.
  • Specific examples include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl and various branched isomers thereof.
  • alkoxy refers to a group having a structure of —O-alkyl, wherein the alkyl is as defined above.
  • C 1-10 alkoxy refers to an alkoxy group having 1 to 10 carbon atoms, preferably, C 1-6 alkoxy, more preferably, C 1-4 alkoxy, the most preferably, C 1-3 alkoxy. Specific examples include, but are not limited to, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy and the like.
  • alkenyl refers to an alkyl as defined above having one or more carbon-carbon double bond at any position of the chain.
  • C 2-8 alkenyl refers to an alkenyl group having 2 to 8 carbon atoms and at least one carbon-carbon double bond, preferably, an alkenyl group having 2 to 6 carbon atoms and 1 to 2 carbon-carbon double bond, i.e., C 2-6 alkenyl, more preferably, an alkenyl group having 2 to 4 carbon atoms and 1 to 2 carbon-carbon double bond, i.e., C 2-4 alkenyl.
  • Specific examples include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, pentenyl, hexenyl, butadienyl, and the like.
  • alkynyl refers to an alkyl as defined above having one or more carbon-carbon triple bond at any position of the chain.
  • C 2-8 alkynyl refers to an alkynyl group having 2 to 8 carbon atoms and at least one carbon-carbon triple bond, preferably, an alkynyl group having 2 to 6 carbon atoms and 1 to 2 carbon-carbon triple bond, i.e., C 2-6 alkynyl, more preferably, an alkynyl group having 2 to 4 carbon atoms and 1 to 2 carbon-carbon triple bond, i.e., C 2-4 alkynyl. Specific examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, and the like.
  • halogen refers to fluoro, chloro, bromo and iodine.
  • haloalkyl refers to an alkyl as defined above which is substituted by one or more (1, 2, 3, 4 or 5) halogens.
  • halo C 1-10 alkyl refers to a haloalkyl having 1 to 10 carbon atoms, preferably, halo C 1-6 alkyl, more preferably, halo C 1-4 alkyl, most preferably, halo C 1-3 alkyl.
  • Specific examples include, but are not limited to, chloromethyl, dichloromethyl, trichloromethyl, chloroethyl, 1,2-dichloroethyl, trichloroethyl, bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, and the like.
  • haloalkoxy refers to an alkoxy as defined above which is substituted by one or more (1, 2, 3, 4 or 5) halogens.
  • halo C 1-10 alkoxy refers to a haloalkoxy having 1 to 10 carbon atoms, preferably, halo C 1-6 alkoxy, more preferably, halo C 1-4 alkoxy, most preferably, halo C 1-3 alkoxy. Specific examples include, but are not limited to, trifluoromethoxy, trifluoroethoxy, fluoromethoxy, fluoroethoxy, difluoromethoxy, difluoroethoxy, and the like.
  • deuterated alkyl refers to an alkyl group substituted with one or more (e.g., 1, 2, 3, 4, or 5) deuterium atoms, wherein the definition of the alkyl group is as described above.
  • deuterated C 1-10 alkyl refers to a deuterated alkyl having 1 to 10 carbon atoms. It is preferably a deuterated C 1-6 alkyl, more preferably a deuterated C 1-4 alkyl, and more preferably a deuterated C 1-3 alkyl.
  • Specific examples include, but are not limited to, mono-deuterated methyl, di-deuterated methyl, tri-deuterated methyl, mono-deuterated ethyl, 1,2-di-deuterated ethyl, tri-deuterated ethyl, and the like.
  • deuterated alkoxy refers to an alkoxy group substituted with one or more (e.g., 1, 2, 3, 4, or 5) deuterium atoms, wherein the alkoxy group is as defined above.
  • deuterated C 1-10 alkoxy refers to a deuterated alkoxy group having 1 to 10 carbon atoms. It is preferably a deuterated C 1-6 alkoxy, more preferably a deuterated C 1-4 alkoxy, and more preferably a deuterated C 1-3 alkoxy.
  • Specific examples include, but are not limited to, tri-deuterated methoxy, tri-deuterated ethoxy, mono-deuterated methoxy, mono-deuterated ethoxy, di-deuterated methoxy, di-deuterated ethoxy, and the like.
  • cycloalkyl and “cycloalkyl ring” refer to saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbyl substituents.
  • the cycloalkyl ring contains 3 to 20 carbon atoms (C 3-20 ), preferably contains 3 to 12 carbon atoms (C 3-12 ), more preferably contains 3 to 10 carbon atoms (C 3-10 ), most preferably contains 3 to 6 carbon atoms (C 3-6 ).
  • a ring carbon atom in a cycloalkyl may be optionally substituted by 1, 2 or 3 oxo group(s) to form a structure of cyclic ketone.
  • the monocyclic cycloalkyl is saturated or partially unsaturated, preferably a monocyclic cycloalkane containing 3 to 8 ring carbon atoms (i.e., 3- to 8-membered or C 3-8 ), more preferably containing 3 to 6 ring carbon atoms.
  • Non-limiting examples of the monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, cyclobutanone, cyclobutan-1,2-dione, cyclopentanone, cyclopentan-1,3-dione, cyclohexanone, cyclohexan-1,3-dione, and the like; the polycyclic cycloalkyl includes spirocycloalkyl, fused cycloalkyl, and bridged cycloalkyl.
  • spirocycloalkyl refers to a polycyclic group containing 5 to 20 ring carbon atoms (i.e., 5- to 20-membered or C 5-20 ), wherein 3- to 8-membered (i.e., containing 3 to 8 ring carbon atoms or C 3-8 ) single rings share one carbon atom (referred to as spiro atom). Each single ring can contain one or more double bonds, but none of the rings has a fully conjugated ⁇ -electron system.
  • It is preferably a 6- to 14-membered (i.e., containing 6 to 14 ring carbon atoms or C 6-14 ) spirocycloalkyl, and more preferably a 7- to 11-membered spirocycloalkyl.
  • the spirocycloalkyls are divided into monospirocycloalkyl, bispirocycloalkyl, or polyspirocycloalkyl, preferably a monospirocycloalkyl and a bispirocycloalkyl, more preferably a 7-membered (4-membered monocyclic/4-membered monocyclic), 8-membered (4-membered monocyclic/5-membered monocyclic), 9-membered (4-membered monocyclic/6-membered monocyclic, 5-membered monocyclic/5-membered monocyclic), 10-membered (5-membered monocyclic/6-membered monocyclic) or 11-membered (6-membered monocyclic/6-membered monocyclic) monospirocycloalkyl.
  • spirocycloalkyl include:
  • the cycloalkyl ring may be fused to an aryl ring, a heteroaryl ring or a heterocyclyl ring, wherein the ring attached to the parent structure is the cycloalkyl ring.
  • Non-limiting examples include indanyl, tetralyl, benzocycloheptyl, and the like.
  • each of the above types of cycloalkyl may be optionally substituted, where the substituent(s) are preferably one or more substituents as described in the present disclosure.
  • halocycloalkyl refers to a cycloalkyl as defined above which is substituted by one or more (1, 2, 3, 4 or 5) halogens.
  • halo C 3-8 cycloalkyl refers to a halocycloalkyl having 3 to 8 carbon atoms, preferably, halo C 3-6 cycloalkyl, more preferably, halo C 3 , halo C 4 , halo C 5 , or halo C 6 cycloalkyl.
  • Specific examples include, but are not limited to, trifluorocyclopropyl, fluorocyclopropyl, fluorocyclohexyl, difluorocyclopropyl, difluorocyclohexyl, and the like.
  • heterocyclyl and “heterocyclyl ring” are used exchangeably to refer to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbyl, containing 3 to 20 ring atoms (i.e., 3- to 20-membered or C 3-20 ), wherein one or more (preferably 1 to 4) ring atoms are heteroatoms selected from the group consisting of nitrogen, oxygen or S(O) m , (wherein m is an integer from 0 to 2), but not contain a cyclic moiety of —O—O—, —O—S— or —S—S—, and the remaining ring atoms are each carbon.
  • the nitrogen atom may be substituted or unsubstituted (i.e., N or NR, R is hydrogen, or other substituents as defined herein).
  • the ring carbon atoms of the heterocyclyl may be optionally substituted by 1, 2 or 3 oxo group(s) to form a structure of cyclic ketone, cyclic lactone or cyclic lactam. It preferably contains 3 to 12 ring atoms, more preferably 3 to 10 ring atoms, wherein 1 to 4 are heteroatoms.
  • heterocyclyl refers to a monocyclic heterocyclyl, which is saturated or partially unsaturated, and preferably a monocyclic heterocyclyl containing 3 to 8 ring atoms (i.e., 3- to 8-membered or C 3-8 ), wherein 1 to 3 are heteroatoms, more preferably a monocyclic heterocyclyl group containing 3 to 6 ring atoms, wherein 1 to 2 are heteroatoms, the most preferably a monocyclic heterocyclyl group containing 5 to 6 ring atoms, wherein 1 to 2 are heteroatoms.
  • the heteroatom is a nitrogen atom
  • the nitrogen atom may be substituted or unsubstituted (i.e., N or NR, R is hydrogen or other substituents as defined herein).
  • the heteroatom is a sulfur atom
  • the sulfur atom may be optionally oxidized (i.e., S(O) m , m is an integer from 0 to 2).
  • the ring carbon atom in the monocyclic heterocyclyl may be optionally substituted by 1, 2 or 3 oxo group(s) to form a structure of cyclic ketone, cyclic lactone or cyclic lactam.
  • the monocyclic heterocyclyl includes, but are not limited to, aziridine, oxirane, azetidine, azetidin-2-one, oxetane, oxetan-2-one, oxazolidine, pyrrolidin-2-one, pyrrolidin-2,5-dione, 1,3-dioxolane, dihydrofuran-2 (3H)-one, dihydrofuran-2,5-dione, piperidin-2-one, piperidin-2,6-dione, tetrahydro-2H-pyran-2-one, imidazolidine, tetrahydrofuran, tetrahydrothiophene, tetrahydropyrrole, 1,3-dioxolan-2-one, oxazolidin-2-one, imidazolidine-2-one, piperidine, piperazine, piperazin-2-one, morpholine, morpholin-3-one,
  • the adjacent two ring atoms in the above monocyclic heterocyclyl may be optionally fused to the cycloalkyl, heterocyclyl, aryl or heteroaryl as defined herein, such as, monocyclic cycloalkyl ring, monocyclic heterocyclyl ring, monoaryl ring, 5- or 6-membered monoheteroaryl ring and the like, to form a fused polycyclyl.
  • the adjacent two ring atoms in the above monocyclic heterocyclyl fused to another ring is preferably C—C.
  • each of the above types of heterocyclyl may be optionally substituted. If substituted, the substituent(s) are preferably one or more substituents as described in the present disclosure.
  • aryl refers to an all-carbon monocyclyl, all-carbon polycyclyl (a ring is linked to another by a covalent bond, non-fused) or all-carbon fused polycyclyl (i.e., a pair of adjacent carbon atoms are shared between the ring) groups containing 6 to 14 ring atoms (i.e., 6- to 14-membered or C 6-14 ), and at least one ring in the ring system is aromatic, that is, has a n electron conjugated system. It is preferably an aryl containing 6 to 10 ring atoms (i.e., 6- to 10-membered or C 6-10 ). Each ring in the ring system contains 5 or 6 ring atoms.
  • aryl and “aryl ring” are used interchangeably.
  • aryl refers to a monoaryl or polyaryl ring, and non-limiting examples thereof include: phenyl, biphenyl, and the like.
  • aryl refers to an aromatic fused polycyclyl
  • the aromatic fused polycyclyl maybe a polycyclyl group formed by fusing a monoaryl ring to one or more monoaryl rings.
  • Non-limiting examples include naphthyl, anthryl, and the like.
  • aryl refers to an aromatic fused polycyclyl (preferably a 9- or 10-membered aromatic fused polycyclyl), the aromatic fused polycyclyl may be a polycyclyl group formed by fusing a monoaryl ring (preferably phenyl) to one or more non-aromatic rings, wherein the ring attached to the parent structure is an aromatic or non-aromatic ring.
  • the non-aromatic ring includes, but is not limited to, a 3- to 6-membered monocyclic heterocyclyl ring, preferably a 5- or 6-membered monocyclic heterocyclyl ring (the ring carbon atom in the monocyclic heterocyclyl may be substituted by 1 or 2 oxo group(s) to form a structure of cyclic lactam or cyclic lactone), a 3- to 6-membered monocyclic cycloalkyl ring, preferably a 5- or 6-membered monocyclic cycloalkyl ring (the ring carbon atom in the monocyclic cycloalkyl may be substituted by 1 or 2 oxo group(s) to form a structure of cyclic ketone), and the like.
  • the above polycyclyl group formed by fusing a monoaryl ring to one or more non-aromatic rings may be linked to other moiety or the parent structure through a nitrogen atom or carbon atom.
  • the ring attached together to the parent structure is an aromatic or non-aromatic ring, and non-limiting examples include:
  • each of the above types of aryl may be substituted or unsubstituted. If substituted, the substituent(s) are preferably one or more groups as described in the present disclosure.
  • heteroaryl refers to a monocyclic or fused polycyclic (that is, rings sharing adjacent carbon atoms or pairs of heteroatoms) groups containing 1 to 4 heteroatoms, having 5 to 14 ring atoms (i.e., 5- to 14-membered or C 5-14 ), preferably 5 to 10 ring atoms (i.e., 5- to 10-membered or C 5-10 ), more preferably 5, 6, 8, 9 or 10 ring atoms, wherein the heteroatoms are selected from the group consisting of oxygen, sulfur and nitrogen, wherein the nitrogen and sulfur atoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized.
  • the heteroaryl in the ring system has 6, 10 or 14 ⁇ electrons as shared. At least one ring in the ring system is aromatic.
  • heteroaryl and “heteroaryl ring” are used interchangeably.
  • heteroaryl refers to a monoheteroaryl ring (preferably a 5- or 6-membered monoheteroaryl ring), and non-limiting examples of the monoheteroaryl include: thiophene, N-alkylcyclopyrrole, furan, thiazole, isothiazole, imidazole, oxazole, pyrrole, pyrazole, triazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, tetrazole, isoxazole, oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, and the like.
  • heteroaryl refers to a fused polyheteroaryl ring (preferably a 8- to 10-membered biheteroaryl ring).
  • the fused polyheteroaryl ring either includes a polycyclic group (preferably a 9- or 10-membered biheteroaryl ring) formed by fusing a monoaryl ring (preferably, phenyl) and a monoheteroaryl ring (preferably a 5- or 6-membered monoheteroaryl ring), or include a polycyclic group (preferably a 8- to 10-membered biheteroaryl ring) formed by fusing a monoheteroaryl (preferably a 5- or 6-membered monoheteroaryl) and a monoheteroaryl (preferably a 5- or 6-membered monoheteroaryl).
  • any 2 adjacent ring atoms in the above monoheteroaryl ring may be fused to the cycloalkyl, heterocyclyl, aryl or heteroaryl such as the monocyclic cycloalkyl ring, monocyclic heterocyclyl ring, monoaryl ring, 5- or 6-membered monoheteroaryl ring and the like as define in the present disclosure, to form a fused polycyclyl.
  • the 2 adjacent ring atoms in the monoheteroaryl ring, which are fused to another ring to form a fused ring are preferably C—C, and include in a non-limiting way the forms of:
  • Non-limiting examples of the fused polyheteroaryl ring include: benzo[d]isoxazole, 1H-indole, isoindole, 1H-benzo[d]imidazole, benzo[d]isothiazole, 1H-benzo[d][1,2,3]triazole, benzo[d]oxazole, benzo[d]thiazole, indazole, benzofuran, benzo[b]thiophene, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, pyrido[3,2-d]pyrimidine, pyrido[2,3-d]pyrimidine, pyrido[3,4-d]pyrimidine, pyrido[4,3-d]pyrimidine, 1,8-naphthyridine, 1,7-naphthyridine, 1,6-naphthyridine, 1,5-naphthyr
  • the above monoheteroaryl, or polycyclyl group formed by fusing a monoaryl ring and a monoheteroaryl ring, or polycyclyl group formed by fusing a monoheteroaryl and a monoheteroaryl may be linked to other moiety or the parent structure through a nitrogen atom or carbon atom. If it is a polycyclyl group, the ring attached together to the parent structure is a heteroaryl ring, an aryl ring, a monocyclic cycloalkyl ring or a monocyclic heterocyclyl ring, and non-limiting examples thereof include:
  • heteroaryl refers to a fused polyheteroaryl ring (preferably a 8- to 10-membered biheteroaryl ring).
  • the fused polyheteroaryl ring is a polycyclyl group formed by fusing a monoheteroaryl ring (preferably a 5- or 6-membered monoheteroaryl ring) and one or more non-aromatic ring(s), wherein the ring attached together to the parent structure is a heteroaryl ring or a non-aromatic ring, the non-aromatic ring includes, but not limited to: a 3- to 6-membered (preferably a 5- or 6-membered) monocyclic heterocyclyl ring (the ring carbon atoms in the monocyclic heterocyclyl ring may be substituted by 1 or 2 oxo group(s) to form a structure of cyclic lactam or cyclic lactone), a 3- to 6-membered (preferably
  • the above polycyclyl group formed by fusing a monoheteroaryl ring and one or more non-aromatic ring(s) may be linked to other moiety or the parent structure through a nitrogen atom or carbon atom, the ring attached together to the parent structure is a heteroaryl ring or a non-aromatic ring, and non-limiting examples thereof include:
  • each of the above types of heteroaryl may be substituted or unsubstituted.
  • the substituent(s) are preferably one or more substituents as described in the present disclosure.
  • hydroxyl refers to —OH.
  • hydroxylmethyl refers to —CH 2 OH
  • hydroxyethyl refers to —CH 2 CH 2 OH or —CH(OH)CH 3 .
  • cyanomethyl refers to —CH 2 CN
  • cyanoethyl refers to —CH 2 CH 2 CN or —CHCNCH 3 .
  • amino refers to —NH 2 .
  • cyano refers to —CN
  • nitro refers to —NO 2 .
  • benzyl refers to —CH 2 -phenyl.
  • oxo group refers to ⁇ O.
  • carboxylic ester group refers to —C(O)O(alkyl) or —C(O)O(cycloalkyl).
  • acetyl refers to —COCH 3 .
  • —C 1-4 alkyl-C 6-10 aryl refers to C 1-4 alkyl is substituted by C 6-10 aryl, preferably substituted by one C 6-10 aryl, wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • —C 1-4 alkyl-C 5-10 heteroaryl refers to C 1-4 alkyl is substituted by C 5-10 heteroaryl, preferably substituted by one C 5-10 heteroaryl, wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • —C 1-4 alkyl-C 3-6 monocyclic heterocyclyl refers to C 1-4 alkyl is substituted by C 3-6 monocyclic heterocyclyl, preferably substituted by one C 3-6 monocyclic heterocyclyl, wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • —C 1-4 alkyl-C 3-6 monocyclic cycloalkyl refers to C 1-4 alkyl is substituted by C 3-6 monocyclic cycloalkyl, preferably substituted by one C 3-6 monocyclic cycloalkyl, wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • —C 1-4 alkyl-hydroxy refers to C 1-4 alkyl is substituted by hydroxy, preferably substituted by one hydroxy, wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —, and the examples of —C 1-4 alkyl-hydroxy include hydroxymethyl, hydroxyethyl.
  • —C 1-4 alkyl-cyano refers to C 1-4 alkyl is substituted by cyano, preferably substituted by one cyano, wherein —C 1-4 alkyl-represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —, and the examples of —C 1-4 alkyl-cyano include cyanomethyl, cyanoethyl.
  • —C 1-4 alkyl-C 1-6 alkoxy refers to C 1-4 alkyl is substituted by C 1-6 alkoxy, preferably substituted by one C 1-6 alkoxy, wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • —C 1-4 alkyl-halo C 1-6 alkyl refers to C 1-4 alkyl is substituted by halo C 1-6 alkyl, preferably substituted by one halo C 1-6 alkyl, wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • —C 1-4 alkyl-halo C 1-6 alkoxy refers to C 1-4 alkyl is substituted by halo C 1-6 alkoxy, preferably substituted by one halo C 1-6 alkoxy, wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • —C 1-4 alkyl-NR e R f refers to C 1-4 alkyl is substituted by NR e R f , preferably substituted by one NR e R f , wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • —C 1-4 alkyl-C(O)NR e R f refers to C 1-4 alkyl is substituted by C(O)NR e R f , preferably substituted by one C(O)NR e R f , wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • —C 1-4 alkyl-SO 2 C 1-3 alkyl refers to C 1-4 alkyl is substituted by SO 2 C 1-3 alkyl, preferably substituted by one SO 2 C 1-3 alkyl, wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • —C 1-4 alkyl-C 2-4 alkynyl refers to C 1-4 alkyl is substituted by C 2-4 alkynyl, preferably substituted by one C 2-4 alkynyl, wherein —C 1-4 alkyl- represents an alkylene or alkylidene radical formed by substitution, and is preferably —C 1-4 alkyl-, more preferably —C 1-3 alkyl-, more preferably —C 1-2 alkyl-, such as —CH 2 —CH 2 —, the most preferably —CH 2 —.
  • substituted means that any one or more hydrogen atoms on a particular atom are replaced with substituents, including deuterium and hydrogen variants, as long as the valence of a particular atom is normal and the substituted compound is stable.
  • substituent is an oxo group (i.e., ⁇ O)
  • ⁇ O oxo group
  • replacement of an oxo group does not occur on aromatic groups.
  • optionally substituted means that it may or may not be substituted. Unless otherwise specified, the type and number of substituents may be arbitrary on the basis of being chemically achievable.
  • any variant e.g., R
  • its definition in each case is independent.
  • the group may optionally be substituted with up to two R, and R in each case has an independent option.
  • substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
  • the compound represented by the formula (I) or formula (II) of the present invention may be prepared by using a synthetic method known in the art or using a method known in the art in combination with the method described in the present invention.
  • the solvent, temperature and other reaction conditions provided by the present invention are exemplary and may be changed according to methods well known in the art.
  • the compounds described in the Examples of the present invention may be synthesized by using appropriate starting materials according to the methods described in the Examples based on their specific structures. It may be synthesized using a method similar to that described in the Examples.
  • the starting materials used to synthesize the compounds in the Examples of the present invention may be prepared by known synthetic methods or similar methods described in the literature or obtained from commercial sources. If necessary, the compounds in the Examples may be further resolved to obtain its stereoisomers by methods well known in the art, such as crystallization, chromatography, and the like, and the resolution conditions are easily obtained by those skilled in the art through conventional means or limited experiments.
  • the compound of formula ((I-a) of the present invention may be synthesized by the following method, wherein the solvent, temperature and other reaction conditions in each step may be the same as or similar to those described in the following Examples, or the reaction conditions known in the art are used;
  • R lev is a well known leaving group in the art, such as trifluoromethanesulfonate; chlorine, bromine, iodine; sulfonate group, such as mesylate, tosylate, p-toluenesulfonate, and the like; acyloxy group, such as acetoxy, trifluoroacetoxy, and the like.
  • R p is an amino protecting group well known in the art, such as formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethyloxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di-(4′-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), and the like.
  • acyl such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such
  • R 1 , R 2 , R 01 , R 02 , R 03 , R 04 , R 05 , R 06 , n, X 1 , X 2 , R a , R b , R c are as defined above.
  • the compound of formula ((II-a) of the present invention may be synthesized by the following method, wherein the solvent, temperature and other reaction conditions in each step may be the same as or similar to those described in the following Examples, or the reaction conditions known in the art are used;
  • R lev is a well known leaving group in the art, such as trifluoromethanesulfonate; chlorine, bromine, iodine; sulfonate group, such as mesylate, tosylate, p-toluenesulfonate, and the like; acyloxy group, such as acetoxy, trifluoroacetoxy, and the like.
  • R p is an amino protecting group well known in the art, such as formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethyloxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di-(4′-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), and the like.
  • acyl such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such
  • R 1 , R 2 , R 01 , R 02 , R 03 , R 04 , R 05 , R 06 , n, X 1 , X 2 , R a , R b ′, R c ′ are as defined above.
  • the compound of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments obtained by combining those listed below with other chemical synthesis methods, and the equivalent alternatives well known to those skilled in the art.
  • Preferred embodiments include, but are not limited to, the Examples of the present invention.
  • the absolute configuration of the stereoisomer separated in the following Examples is arbitrarily specified, and the separation method may be chromatographic separation, for example, including but not limited to column chromatography, thin layer chromatography, liquid chromatography, and the like.
  • CDI is N,N′-carbonyl diimidazole
  • DBU is 1,8-diazabicyclo[5.4.0]undec-7-ene
  • PyBop is 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate
  • SPhos is 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl
  • SPhos-Pd-G2 is chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl) [2-(2′-amino-1,1′-biphenyl)]palladium(II)
  • LiHMDS is lithium bis(trimethylsilyl)amide
  • Selectfluor is 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluor
  • Step 1 2-isopropyl-4-methylpyridine-3-amine (50 g, 333.3 mmol) was dissolved in tetrahydrofuran (500 mL) and the reaction solution was cooled to ⁇ 65° C., then NaHMDS (333.3 mL, 2M, 666.6 mmol) was slowly dropped, and the reaction solution was kept lower than ⁇ 60° C. during the dropping process. After the completion of the dropping, the reaction proceeded at ⁇ 60° C. for 30 minutes, then 4-bromo-2,6-difluorobenzonitrile in tetrahydrofuran (500 mL) was slowly dropped to the reaction solution, and the reaction solution was kept lower than ⁇ 60° C. during the dropping process.
  • Step 2 4-bromo-2-fluoro-6-((2-isopropyl-4-methylpyridin-3-yl)amino)benzonitrile (13 3 g, the crude product, 333.3 mmol) was dissolved in acetonitrile (1400 mL), and NCS (89.1 g, 666.6 mmol) was added. The reaction solution was heated to 80° C. to react for 2 hours, cooled to room temperature, and water was added to quench the reaction.
  • Step 3 4-bromo-3-chloro-2-fluoro-6-((2-isopropyl-4-methylpyridin-3-yl)amino)benzo nitrile (13.91 g, 36.5 mmol) was dissolved in DMSO (130 mL), then potassium carbonate (10.0 g, 73.2 mmol) was added, hydrogen peroxide (14.91 g, 131.41 mmol) was dropped under the ice bath, and the reaction proceeded at room temperature for 2 hours. After the completion of the reaction, 10% sodium sulfite solution (100 mL) was slowly added under the ice bath to quench the reaction.
  • Step 4 4-bromo-3-chloro-2-fluoro-6-((2-isopropyl-4-methylpyridin-3-yl)amino)benzamide (12.5 g, 31.33 mmol) in tetrahydrofuran (150 ml) was dropped in a solution of sodium hydride (12.5 g, 156.66 mmol) in tetrahydrofuran (40 mL) under a dry ice ethanol bath to control the temperature below 0° C., the reaction proceeded for 15 minutes under a dry ice ethanol bath, and then carbonyl diimidazole (7.6 g, 47.1 mmol) in tetrahydrofuran (100 mL) was dropped.
  • Step 5 tert-butyl (R) 3-(hydroxymethyl)piperazin-1-carboxylate (3.0 g, 14.07 mmol) was dissolved in THF (60 mL) at 0° C., sodium hydride (1.88 g, 46.9 mmol) was added in batches, the reaction was continued at 0° C. for 30 minutes, then 7-bromo-6-chloro-5-fluoro-4-hydroxy-1-(2-isopropyl-4-methylpyridin-3-yl) quinazolin-2-one (4.0 g, 9.38 mmol) was added in batches, and the reaction solution reacted at 0° C. ⁇ room temperature for 1.5 hours.
  • reaction solution was diluted with ethyl acetate (100 mL) at 0° C., then the ice water was added, the product was extracted with ethyl acetate (3*100 mL), washed with the saturated brine (3*80 mL), dried with anhydrous sodium sulfate, and concentrated to obtain the crude product.
  • Step 6 tert-butyl (R)-3-(((7-bromo-6-chloro-4-hydroxy-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydroquinazolin-5-yl)oxy)methyl)piperazin-1-carboxylate (4.0 g, 6.42 mmol) was dissolved in DMF (100 mL) at 0° C., PyBOP (8.35 g, 16.05 mmol) was added in batches, and then DBU (4.88 g, 32.10 mmol) was dropped. After addition was completed, the reaction solution reacted at room temperature for 2 hours.
  • Step 1 6-bromopyridin-2-ol (866 mg, 4.98 mmol) was dissolved in 5 mL acetonitrile, potassium carbonate (2.06 g, 14.93 mmol) and methyl iodide (1.06 g, 7.47 mmol) were added, and stirred at 60° C. for 2 hours.
  • the reaction solution was extracted with ethyl acetate, and concentrated under reduced pressure.
  • ES-API: [M+H] + 188.0.
  • Step 2 6-bromo-1-methylpyridin-2 (1H)-one (2 g, 10.6 mmol) was dissolved in tetrahydrofuran (20 mL), and cooled to ⁇ 78° C. under nitrogen protection, n-butyl lithium (5.1 mL, 12.7 mmol, 2.5 M in tetrahydrofuran) was dropped. Under stirring, the reaction proceeded for 15 minutes at ⁇ 78° C., and then tributyltin chloride (5.19 g, 16.0 mmol) was dropped, and the reaction slowly dried to room temperature. The reaction solution was quenched with the saturated ammonium chloride solution, extracted with ethyl acetate, concentrated under reduced pressure.
  • Step 1 2,4-dichloro-6-methyl-5-nitropyrimidine (20 g, 97.08 mmol) was dissolved in dioxane (400 ml), isopropylalkenyl potassium trifluoroborate (14.98 g, 101.9 mmol), bis(triphenylphosphine)palladium dichloride (3.4 g, 4.85 mmol) were added in sequence, sodium carbonate (20 g) dissolved in 100 mL of water was dropped thereto. After addition was completed, the nitrogen was used for replacement for three times, and the reaction proceeded for 2 hours at 80° C.
  • Step 2 2-chloro-4-methyl-5-nitro-6-(prop-1-en-2-yl)pyrimidine (8 g, 37.55 mmol) was dissolved in methanol (50 ml), sodium acetate (6.15 g, 75.11 mmol) and 800 mg palladium on carbon were added in sequence. The reaction was connected to hydrogen balloon and the hydrogen was used for replacement for three times. The reaction was stirred at room temperature for 24 hours. The point board was found that the raw materials disappeared, there were products and by-products that had not removed Cl.
  • Step 1 methyl 2-amino-4-bromo-6-fluorobenzoate (2.6 g, 10.48 mmol) and 50 mL isopropanol were added to a 250 mL round bottom flask. After the temperature of the system raising to 60° C., N-chlorosuccinimide (1.7 g, 12.7 mmol) was added to the reaction solution. The temperature of the system rised to 80° C. and reacted at this temperature for 20 minutes. After the completion of the reaction, the reaction solution was concentrated.
  • Step 2 methyl 6-amino-4-bromo-3-chloro-2-fluorobenzoate (1.1 g, 3.89 mmol), 1-iodo-2-isopropylbenzene (1.44 g, 5.84 mmol), Pd 2 (dba) 3 (0.36 g, 0.39 mmol), xantphos (0.56 g, 0.97 mmol), cesium carbonate (2.55 g, 7.78 mmol) and 20 mL of dioxane were added to a 100 mL round bottom flask. The system was replaced with the nitrogen for three times, and then protected with a nitrogen ball. The reaction was stirred at 70° C. for 16 hours. The completion of the reaction was detected by LC-MS.
  • Step 3 methyl 4-bromo-3-chloro-2-fluoro-6-((2-isopropylphenyl)amino)benzoate (380 mg, 0.95 mmol), sodium hydroxide (114 mg, 2.84 mmol), methanol (5 mL), tetrahydrofuran (10 mL) and water (5 mL) were added to a 100 mL round bottom flask. The reaction was stirred at room temperature for 3 hours. The completion of the reaction was detected by LC-MS. 30 mL of water was added to the reaction, and the pH of the reaction was adjusted to 7 with 1M aqueous hydrochloric acid.
  • Step 4 4-bromo-3-chloro-2-fluoro-6-((2-isopropylphenyl)amino)benzoic acid (280 mg, 0.72 mmol), thionyl chloride (862 mg, 7.2 mmol) and toluene (5 mL) were added to a 100 mL round bottom flask. The reaction was stirred at 100° C. for 1 hour. The reaction solution was concentrated and dried to obtain a yellow oil. The yellow oil was dissolved in tetrahydrofuran, and then it was dropped to 28% ammonia water (5 mL). The reaction solution was stirred at room temperature for 1 hour. The completion of the reaction was detected by LC-MS. 30 mL of water was added to the reaction.
  • Step 5 60% NaH (146 mg, 3.65 mmol), tetrahydrofuran (6 mL) and DMF (2 mL) were added to a 100 mL round bottom flask. The reaction was cooled to 0° C., and 4-bromo-3-chloro-2-fluoro-6-((2-isopropylphenyl)amino)benzamide (280 mg, 0.73 mmol) in tetrahydrofuran (2 mL) was dropped thereto. The reaction was stirred at 0° C. for 5 minutes, and then N,N′-carbonyl diimidazole (141 mg, 0.87 mmol) in tetrahydrofuran (1 mL) was dropped to the reaction solution.
  • Step 6 60% NaH (24 mg, 0.6 mmol), tert-butyl 3-(hydroxymethyl)piperazin-1-carboxylate (67 mg, 0.31 mmol), tetrahydrofuran (6 mL) were added to a 100 mL round bottom flask. The reaction was cooled to 0° C., and 7-bromo-6-chloro-5-fluoro-4-hydroxy-1-(2-isopropylphenyl)quinazolin-2 (1H)-one (100 mg, 0.24 mmol) in tetrahydrofuran (2 mL) was dropped thereto. The reaction was stirred at 0° C. for 5 minutes, and then the reaction was stirred under a 65° C.
  • the crude product was purified by a fast silica gel column (methanol/dichloromethane: 0-5%) to obtain the target product: tert-butyl 3-(((7-bromo-6-chloro-4-hydroxy-1-(2-isopropylphenyl)-2-oxo-1,2-dihydro quinazolin-5-yl)oxy)methyl)piperazin-1-carboxylate (130 mg), a yellow solid, purity of 84%, yield of 75%.
  • ES-API: [M+H] + 607.1.
  • Step 7 tert-butyl 3-(((7-bromo-6-chloro-4-hydroxy-1-(2-isopropylphenyl)-2-oxo-1,2-dihydroquinazolin-5-yl)oxy)methyl)piperazin-1-carboxylate (100 mg, 0.16 mmol), N,N-dimethylformamide (1 mL) and 50% T 3 P in ethyl acetate (523 mg, 0.82 mmol) were added to a 50 mL round bottom flask. DBU (146 mg, 0.96 mmol) was added all at once while stirring. The reaction was stirred at room temperature for 16 hours. The completion of the reaction was detected by LC-MS.
  • Step 8 tert-butyl 10-bromo-11-chloro-8-(2-isopropylphenyl)-7-oxo-3,4,7,8,13,13a-hexahydropyr azine[2′,1′: 3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (40 mg, 0.068 mmol), (5-methyl-1H-indazol-4-yl)boronic acid (18 mg, 0.1 mmol), SPhos (7 mg, 0.017 mmol), Pd 2 (dba) 3 (12 mg, 0.014 mmol), potassium phosphate (43 mg, 0.2 mmol), 2 mL of dioxane and 0.2 mL of water were added to a 10 mL microwave reaction tube.
  • the microwave reaction tube was placed in a microwave reactor at 115° C. and the reaction proceeded for 1 hour, and the reaction stopped. 20 mL of water was added to the reaction solution. The reaction solution was extracted with 20 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • the crude product was purified by a fast silica gel column (ethyl acetate/petroleum ether: 0-100%) to obtain the target product: tert-butyl 11-chloro-8-(2-isopropylphenyl)-10-(5-methyl-1H-indazol-4-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazine[2′,1′: 3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (40 mg), a yellow solid, purity of 70%, the crude product yield of 64%.
  • ES-API: [M+H] + 641.2.
  • Step 9 tert-butyl 11-chloro-8-(2-isopropylphenyl)-10-(5-methyl-1H-indazol-4-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazine[2′,1′: 3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (40 mg, 0.062 mmol), 2 mL dichloromethane and 2 mL of trifluoroacetic acid were added to a 25 mL round bottom flask. The reaction was stirred at room temperature for 0.5 hour. The completion of the reaction was detected by LC-MS.
  • Step 10 11-chloro-8-(2-isopropylphenyl)-10-(5-methyl-1H-indazol-4-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′: 3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (39 mg, 0.06 mmol), 2 mL dichloromethane and triethylamine (30 mg, 0.3 mmol) were added to a 25 mL round bottom flask. The reaction was cooled to 0° C., and acrylic anhydride in dichloromethane (5 mg, 0.04 mmol, 0.5 mL) was dropped to the reaction solution.
  • Step 1 2-isopropyl-4-methylpyridin-3-amine (1.5 g, 9.99 mmol) and 50 mL of tetrahydrofuran were added to a 250 mL round bottom flask. After the system cooling to 0° C., sodium bis(trimethylsilyl)amide (12.5 mL, 2.5 M in tetrahydrofuran, 25 mmol) was dropped to the reaction solution. After the completion of the dropping, the reaction was stirred at ⁇ 65° C. for 30 minutes, and then 4-bromo-2,6-difluorobenzonitrile (2.39 g, 10.98 mmol) in tetrahydrofuran (50 mL) was dropped to the reaction solution.
  • Step 2 4-bromo-2-fluoro-6-(((2-isopropyl-4-methylpyridin-3-yl)amino)benzonitrile (1.7 g, 4.88 mmol) and 50 mL of dimethyl sulfoxide were added to a 250 mL three-necked round bottom flask, cooled to 0-5° C. under the ice bath, potassium carbonate (1.34 g, 9.76 mmol) and hydrogen peroxide (6.57 g, 30% aqueous solution, 58 mmol) were added. The reaction proceeded overnight at this temperature. The completion of the reaction was detected by LCMS. The reaction solution was poured into about 150 mL of ice water, and a solid precipitated out.
  • Step 3 4-bromo-2-fluoro-6-(((2-isopropyl-4-methylpyridin-3-yl)amino)benzamide (1.8 g, 4.9 mmol) and 80 mL of dry tetrahydrofuran were added to a 250 mL three-necked round bottom flask, cooled to 0-5° C. under the ice bath, sodium hydride was added in batches (980 mg, 24.5 mmol), and the reaction proceeded at this temperature for 10 minutes. A suspension of CDI (1.59 g, 9.8 mmol) in tetrahydrofuran (40 mL) was dropped to the above solution, and then the reaction proceeded at this temperature for 20 minutes.
  • Step 4 tert-butyl (S)-3-(hydroxymethyl)piperazin-1-carboxylate (1.04 g, 4.81 mmol) was added to a suspension of 60% sodium hydride (1.11 g, 18.5 mmol) in tetrahydrofuran (50 mL) at 0° C., reacted at 0° C. for 30 minutes, and 7-bromo-5-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)quinazolin-2,4(1H, 3H)-dione (1.46 g, 3.7 mmol) in tetrahydrofuran (20 mL) was dropped thereto. The reaction was stirred at 0° C.
  • Step 5 tert-butyl (S)-3-((((7-bromo-1-(2-isopropyl-4-methylpyridin-3-yl)-2,4-dioxo-1,2,3,4-tetra hydroquinazolin-5-yl)oxy)methyl)piperazin-1-formate (1.34 g, 2.29 mmol), DBU (2.01 g, 13.74 mmol), PyBop (3.57 g, 6.87 mmol) dichloromethane (100 mL) were added to a round bottom flask. The reaction was stirred at room temperature for 30 minutes. The completion of the reaction was detected by LC-MS.
  • Step 6 tert-butyl (S)-10-bromo-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (1.04 g, 1.83 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (429 mg, 2.75 mmol), SPhos (73 mg, 0.18 mmol), SPhos-Pd-G2 (129 mg, 0.18 mmol), potassium phosphate (1.16 g, 5.49 mmol), 60 mL of dioxane and 12 mL of water were added to a 100 mL reaction flask.
  • Step 7 tert-butyl (S)-10-(2-fluoro-6-hydroxyphenyl)-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (560 mg, 0.93 mmol), 3 mL of trifluoroacetic acid and 6 mL of dichloromethane were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour. The completion of the reaction was detected by LC-MS.
  • Step 8 (S)-10-(2-fluoro-6-hydroxyphenyl)-8-(2-isopropyl-4-methylpyridin-3-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′: 3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (582 mg, 1.16 mmol), 6 mL of dichloromethane and triethylamine (1.17 g, 11.6 mmol) were added to a round bottom flask. The reaction was cooled to 0° C., and acrylic anhydride in dichloromethane (117 mg, 0.93 mmol, 1 mL) was dropped to the reaction solution.
  • Step 9 Compound Z15 (257 mg, 0.46 mmol) was resolved chirally (mobile phase: methanol (0.2% ammonia methanol)); column type: Cellulose-SC (4.6*100*5 um); flow rate: 1.8 ml/min; column temperature: 40.2° C.) to obtain:
  • Step 1 sodium hydride (0.81 g, 20.25 mmol, 60%) was suspended in 15 ml of tetrahydrofuran solution and cooled to 0° C., and 7-bromo-5-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)quinazolin-2,4(1H, 3H)-dione (1.44 g, 6.658 mmol), 10 ml of tetrahydrofuran solution was slowly dropped to the solution.
  • Step 2 tert-butyl (R)-3-((((7-bromo-1-(2-isopropyl-4-methylpyridin-3-yl)-2,4-dioxo-1,2,3,4-tetra hydroquinazolin-5-yl)oxy)methyl)piperazin-1-carboxylate (1.5 g, 2.55 mmol) was dissolved in N,N-dimethylformamide (50 mL), benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (3.97 g, 7.64 mmol), 1,8-diazabicycloundec-7-ene (2.33 g, 15.29 mmol) were added in sequence.
  • Step 3 tert-butyl (R)-10-bromo-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (200 mg, 0.35 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (82 mg, 0.526 mmol), chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (25.24 mg, 0.035 mmol), 2-dicyclohexylphosphino-2′,6′-dimethoxy-biphenyl (14.37 mg, 0.035
  • the system was replaced with the nitrogen for three times, and then protected with a nitrogen ball.
  • the reaction was stirred at 110° C. for 1 hour.
  • 150 mL of ethyl acetate was added to the reaction solution, the reaction solution was washed with the saturated brine for 3 times, dried and concentrated.
  • Step 4 tert-butyl (R)-10-(2-fluoro-6-hydroxyphenyl)-8-(2-isopropyl-4-methylpyridin-3-yl)-7-ox o-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (160 mg, 0.266 mmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (2 mL) was added.
  • Step 5 (R)-10-(2-fluoro-6-hydroxyphenyl)-8-(2-isopropyl-4-methylpyridin-3-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (175 mg, 0.266 mmol) was dissolved in dichloromethane (15 mL), and triethylamine (1.0 mL, 7.21 mmol) was added. The reaction was cooled to 0° C., and acrylic anhydride (26.83 mg, 0.213 mmol) was dropped to the reaction solution. The reaction was stirred at 0° C.
  • Step 2 4-bromo-2-(cyclopropylamino)-6-fluorobenzonitrile (10 g, 39.21 mmol), N-chlorosuccinimide (5.7 g, 43.13 mmol) and acetonitrile (150 mL) were added to a round bottom flask. The reaction was stirred at 65° C. for 0.5 hour. sodium thiosulfate aqueous solution was added to the reaction solution. The reaction solution was extracted with ethyl acetate. The organic phase was dried and concentrated.
  • Step 3 4-bromo-3-chloro-6-(cyclopropylamino)-2-fluorobenzonitrile (5 g, 17.30 mmol), potassium carbonate (4.77 g, 34.60 mmol) and dimethyl sulfoxide (30 mL) were added to a round bottom flask. 30% hydrogen peroxide (3.47 mL, 34.60 mmol) was added under stirring. The reaction was stirred at room temperature for 3 hours. Ice water was added to the reaction solution, and a solid precipitated out. It was filtered and the filter cake was vacuum-dried to obtain 4-bromo-3-chloro-6-(cyclopropylamino)-2-fluorobenzamide (4.7 g, 89%), a white solid.
  • Step 4 4-bromo-3-chloro-6-(cyclopropylamino)-2-fluorobenzamide (4.7 g, 16.7 mmol) and 80 mL of dry tetrahydrofuran were added to a round bottom flask, cooled to 0-5° C. under the ice bath, sodium hydride (3.3 g, 83.5 mmol) was added in batches, the reaction proceeded at this temperature for 5 minutes. A suspension of CDI (3.2 g, 20.04 mmol) in tetrahydrofuran (40 mL) was dropped to the above solution, and then the reaction proceeded at this temperature for 15 minutes. The completion of the reaction was detected by LCMS.
  • reaction solution was poured into about 150 mL of ice water, and the pH was adjusted to about 3 with 3 M hydrochloric acid.
  • the reaction solution was extracted with ethyl acetate.
  • the organic phase was washed with the saturated brine, dried with anhydrous sodium sulfate, and filtered.
  • the filtrate was concentrated and dried to obtain 7-bromo-6-chloro-1-cyclopropyl-5-fluoro-4-hydroxyquinazolin-2 (1H)-one (3 g, 55%), a yellow solid, the crude product was directly used in the next step.
  • ES-API: [M+H] + 333.1.
  • Step 5 60% NaH (180 mg, 4.5 mmol), tert-butyl (S)-3-(hydroxymethyl)piperazin-1-carboxylate (291 mg, 1.35 mmol), tetrahydrofuran (12 mL) were added to a round bottom flask. The reaction was cooled to 0° C., and a solution of 7-bromo-6-chloro-1-cyclopropyl-5-fluoro-4-hydroxyquinazolin-2 (1H)-one (300 mg, 0.90 mmol) in tetrahydrofuran (3 mL) was dropped thereto. The reaction was stirred at 0° C. for 5 minutes, and then the reaction was stirred under a 60° C. oil bath for 1 hour.
  • Step 6 tert-butyl (S)-3-((((7-bromo-6-chloro-1-cyclopropylmethyl-4-hydroxy-2-oxo-1,2-dihydro quinazolin-5-yl)oxy)methyl)piperazin-1-carboxylate (450 mg, 0.85 mmol), 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (1.3 g, 2.55 mmol) N,N-dimethylformamide (8 mL) were added to a round bottom flask. DBU (646 mg, 4.25 mmol) was added under stirring. The reaction was stirred at room temperature for 2 hours. The completion of the reaction was detected by LC-MS.
  • Step 7 tert-butyl (S)-10-bromo-11-chloro-8-cyclopropyl-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (370 mg, 0.72 mmol), (5-methyl-1H-indazol-4-yl)boronic acid (190 mg, 1.08 mmol), SPhos (29 mg, 0.072 mmol), SPhos-Pd-G 2 (52 mg, 0.072 mmol), potassium phosphate (457 mg, 2.16 mmol), 8 mL of dioxane and 2 mL of water were added to a round bottom flask.
  • the round bottom flask was placed in a microwave reactor at 105° C. and the reaction proceeded for 2 hours, and the reaction stopped. 20 mL of water was added to the reaction solution. The reaction solution was extracted with 20 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • the crude product was purified by a fast silica gel column (methanol/dichloromethane: 0-2%) to obtain the target product: tert-butyl (13aS)-11-chloro-8-cyclopropyl-10-(5-methyl-1H-indazol-4-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (400 mg), a yellow solid, purity of 60%, yield of 59%.
  • ES-API: [M+H] + 563 0.2.
  • Step 8 tert-butyl (13aS)-11-chloro-8-cyclopropyl-10-(5-methyl-1H-indazol-4-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (400 mg, 0.44 mmol), 3 mL of dichloromethane and 3 mL of trifluoroacetic acid were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour. The completion of the reaction was detected by LC-MS.
  • Step 9 (13aS)-11-chloro-8-cyclopropyl-10-(5-methyl-1H-indazol-4-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (203 mg, 0.44 mmol), 5 mL of dichloromethane and triethylamine (222 mg, 2.2 mmol) were added to a round bottom flask. The reaction was cooled to 0° C., acrylic anhydride in dichloromethane (39 mg, 0.3 mmol, 0.5 mL) was dropped to the reaction solution.
  • the reaction was stirred at 0° C. for 10 minutes. 10 mL of the saturated NaHCO 3 aqueous solution was added to the reaction solution, and the reaction solution was extracted with 10 mL of dichloromethane for 3 times. The organic phase was dried and concentrated, and the crude product was purified by Preparative HPLC to obtain the target product: Z17 (55.94 mg, 24%), a white solid.
  • Step 1 tert-butyl (S)-10-bromo-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (500 mg, 0.9 mmol), (5-methyl-1H-indazol-4-yl)boronic acid (238 mg, 1.35 mmol), SPhos (37 mg, 0.09 mmol), SPhos-Pd-G2 (65 mg, 0.09 mmol), potassium phosphate (600 mg, 2.25 mmol), 60 mL of dioxane and 12 mL of water were added to a 100 mL reaction flask.
  • the reaction was stirred at 115° C. for 2 hours under nitrogen protection, and the reaction stopped. 50 mL of water was added to the reaction solution. The reaction solution was extracted with 50 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • Step 2 tert-butyl (R)-8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (346 mg, 0.56 mmol), 3 mL of trifluoroacetic acid and 6 mL of dichloromethane were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour. The completion of the reaction was detected by LC-MS.
  • Step 3 (R)-8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (361 mg, 0.69 mmol), 10 mL of dichloromethane and triethylamine (700 mg, 6.9 mmol) were added to a round bottom flask.
  • the reaction was cooled to 0° C., and acrylic anhydride in dichloromethane (69 mg, 0.55 mmol, 1 mL) was dropped to the reaction solution.
  • the reaction was stirred at 0° C. for 10 minutes.
  • 40 mL of the saturated sodium bicarbonate aqueous solution was added to the reaction solution, and the reaction solution was extracted with 20 mL of dichloromethane for 3 times.
  • Step 1 tert-butyl (S)-10-bromo-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (500 mg, 0.9 mmol), (5-methyl-1H-indazol-4-yl)boronic acid (238 mg, 1.35 mmol), SPhos (37 mg, 0.09 mmol), SPhos-Pd-G2 (65 mg, 0.09 mmol), potassium phosphate (600 mg, 2.25 mmol), 60 mL of dioxane and 12 mL of water were added to a 100 mL reaction flask.
  • the reaction was stirred at 115° C. for 2 hours under nitrogen protection, and the reaction stopped. 50 mL of water was added to the reaction solution. The reaction solution was extracted with 50 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • Step 2 tert-butyl (S)-8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (381 mg, 0.61 mmol), 3 mL of trifluoroacetic acid and 6 mL of dichloromethane were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour. The completion of the reaction was detected by LC-MS.
  • Step 3 (S)-8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (401 mg, 0.96 mmol), 10 mL of dichloromethane and triethylamine (971 mg, 9.6 mmol) were added to a round bottom flask.
  • the reaction was cooled to 0° C., and a solution of acrylic anhydride in dichloromethane (97 mg, 0.77 mmol, 1 mL) was dropped to the reaction solution.
  • the reaction was stirred at 0° C. for 10 minutes.
  • 40 mL of the saturated sodium bicarbonate aqueous solution was added to the reaction solution, and the reaction solution was extracted with 20 mL of dichloromethane for 3 times.
  • Example 20 Preparation of Compound Z20, Z20-1, Z20-2, Z20-3 and Z20-4
  • Step 1 methyl 6-amino-4-bromo-3-chloro-2-fluorobenzoate (6.3 g, 22.35 mmol), (5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)boronic acid (9.3 g, 35.77 mmol), 2-bicyclohexylphosphin-2′,6′-dimethoxybiphenyl (734 mg, 1.78 mmol), SPhos-Pd-G2 (1.27 g, 1.78 mmol), potassium phosphate (14.2 g, 67.05 mmol), 100 mL of dioxane and 20 mL of water were added to a reaction flask.
  • Step 2 methyl 6-amino-3-chloro-2-fluoro-4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)benzoate (6.2 g, 14.8 mmol), 1-iodo-2-isopropylbenzene (5.4 g, 22.2 mmol), XantPhos-Pd-G2 (0.92 g, 1.03 mmol), 4,5-bisdiphenylphosphino-9,9-dimethylxanthene (0.60 g, 1.03 mmol), cesium carbonate (9.7 g, 29.6 mmol), and 120 mL of toluene were added to a round bottom flask.
  • the system was replaced with the nitrogen for three times, and then protected with a nitrogen ball.
  • the reaction was stirred at 90° C. for 21 hours. The completion of the reaction was detected by LC-MS. Water was added to the reaction solution. The reaction solution was extracted with ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • Step 3 methyl 3-chloro-2-fluoro-6-(((2-isopropylphenyl)amino)-4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)benzoate (6.5 g, 12.1 mmol), sodium hydroxide (1.5 g, 36.4 mmol), methanol (50 mL), tetrahydrofuran (50 mL) and water (20 mL) were added to a round bottom flask. The reaction was stirred at 45° C. for 1 hour. The completion of the reaction was detected by LC-MS.
  • Step 4 3-chloro-2-fluoro-6-((2-isopropylphenyl)amino)-4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)benzoic acid (6.3 g, 12.1 mmol), ammonium chloride (1.9 g, 36.2 mmol), 2-(7-azobenzotriazole)-N,N,N′,N′-tetramethylurea hexafluorophosphate (6.9 g, 18.2 mmol), dichloromethane (40 mL), N,N-dimethylformamide (20 mL) and triethylamine (6.1 g, 60.5 mmol) were added to the round bottom flask in sequence at 0° C.
  • Step 5 60% NaH (2.3 g, 58.5 mmol) and tetrahydrofuran (60 mL) were added to a round bottom flask. The reaction was cooled to 0° C., and a solution of 3-chloro-2-fluoro-6-(((2-isopropylphenyl)amino)-4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)benzamide (6.1 g, 11.7 mmol) in tetrahydrofuran (20 mL) was dropped thereto. The reaction was stirred at 0° C.
  • Step 6 60% NaH (2.3 g, 57.5 mmol), tert-butyl (S)-3-(hydroxymethyl)piperazin-1-carboxylate (4 g, 18.4 mmol), tetrahydrofuran (100 mL) were added to a round bottom flask.
  • Step 7 tert-butyl (3S)-3-((((6-chloro-4-hydroxy-1-(2-isopropylphenyl)-7-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-2-oxo-1,2-dihydroquinazolin-5-yl)oxy)meth ylpiperazin-1-formate (6 g, 8.1 mmol), N,N-dimethylformamide (40 mL) and 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (10.5 g, 20.2 mmol) were added to a round bottom flask.
  • Step 8 tert-butyl (13aS)-11-chloro-8-(2-isopropylphenyl)-10-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-7 oxo 3,4,7,8,13,13a hexahydropyrazino[2′,1′: 3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxy late (4.1 g, 5.6 mmol), 5 mL of dichloromethane and 20 mL of trifluoroacetic acid were added to a round bottom flask. The reaction was stirred at room temperature for 2 hours.
  • Step 9 (13aS)-11-chloro-8-(2-isopropylphenyl)-10-(5-methyl-1H-indazol-4-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (3 g, 5.6 mmol), 20 mL of dichloromethane and triethylamine (2.8 g, 28 mmol) were added to a round bottom flask. The reaction was cooled to 0° C., and acrylic anhydride (635 mg, 5.04 mmol) was added to the reaction solution.
  • the reaction was stirred at 0° C. for 20 minutes. 100 mL of the saturated NaHCO 3 aqueous solution was added to the reaction solution, and the reaction solution was extracted with dichloromethane for 3 times. The organic phase was dried and concentrated, and the crude product was purified by Preparative HPLC to obtain the target product: Z20 (1.1 g, 33%), a white solid.
  • Step 2 4-bromo-2-(cyclopropylamino)-6-fluorobenzonitrile (52.0 g, 0.204 mol), potassium carbonate (55.5 g, 0.408 mol) and 500 mL of dimethyl sulfoxide were added to a 1000 mL three-necked round bottom flask. 30% hydrogen peroxide (93.0 g, 0.734 mol) was slowly dropped at room temperature, The reaction solution was stirred for 3 hours at room temperature.
  • Step 3 4-bromo-2-(cyclopropylamino)-6-fluorobenzonitrile (13.2 g, 0.048 mol) and 150 mL of anhydrous tetrahydrofuran were added to a 500 mL three-necked round bottom flask. The system was replaced with the nitrogen for three times, and then protected with a nitrogen ball. sodium hydride (9.62 g, 0.240 mol) was added at 0° C., the reaction proceeded for 0.5 hour keeping this temperature, and a solution of N,N′-carbonyl diimidazole in anhydrous tetrahydrofuran (1.44 mol/L, 50 mL) was quickly added.
  • Step 4 tert-butyl 3-(2-hydroxyethyl)piperazin-1-formate (6.1 g, 0.026 mol) and 80 mL of anhydrous tetrahydrofuran were added to a 250 mL three-necked round bottom flask, the system was replaced with the nitrogen for three times, and then protected with a nitrogen ball.
  • Step 5 tert-butyl 3-(2-(((7-bromo-1-cyclopropyl-4-hydroxy-2-oxo-1,2-dihydroquinazolin-5-yl)oxy)ethyl)piperazine-1-formate (3.0 g, 0.006 mol), 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (9.3 g, 0.018 mol), 1,8-diazabicyclo[5.4.0]undec-7-ene (4.56 g, 0.03 mol) and 50 mL of N,N-dimethylformamide were added to a 100 mL three-necked round bottom flask, and stirred at room temperature for 2 hours.
  • Step 6 tert-butyl 10-bromo-8-cyclopropyl-7-oxo-1,3,4,7,8,13,14,14a-octahydro-2H-pyrazino[1′,2′:5,6][1,5]oxazoline[4,3,2-de]quinazolin-2-carboxylate (0.49 g, 0.001 mol), (5-methyl-1H-indazol-4-yl)boronic acid (0.260 g, 0.0015 mol), chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (0.072 g, 0.0001 mol), SPhos (0.041 g, 0.0001 mol), potassium phosphate (0.64 g, 0.003 mol), 10 mL of dioxane and 2 mL of water were
  • the system was replaced with the nitrogen for three times, and then protected with a nitrogen ball.
  • the reaction proceeded at 110° C. for 2 hours.
  • 30 mL of ethyl acetate was added to the reaction solution, the reaction solution was washed with 30 mL of the saturated brine for 3 times, dried and concentrated.
  • Step 7 tert-butyl 8-cyclopropyl-10-(5-methyl-1H-indazol-4-yl)-7-oxo-1,3,4,7,8,13,14,14a-octahydro-2H-pyrazino[1′,2′:5,6][1,5]oxazolidine[4,3,2-de]quinazolin-2-carboxylate (550 mg, 0.001 mol) was dissolved in dichloromethane (8 mL), and trifluoroacetic acid (2 mL) was added.
  • Step 8 8-cyclopropyl-10-(5-methyl-1H-indazol-4-yl)-1,3,4,13,14,14a-hexahydro-2H-pyrazino[1′,2′:5,6][1,5]oxazolidine[4,3,2-de]quinazolin-7
  • 8H)-one 500 mg, 0.0011 mol was dissolved in dichloromethane (15 mL), and triethylamine (0.034 g, 0.0003 mol) was added. The reaction was cooled to 0° C., and acrylic chloride (138 mg, 0.0011 mol) was dropped to the reaction solution. The reaction was stirred at 0° C. for 15 minutes.
  • Step 1 Tert-butyl 3-(2-hydroxyethyl)piperazin-1-formate (1.76 g, 7.65 mmol) was added to a suspension of sodium hydride (404 mg, 10.20 mmol) in tetrahydrofuran (40 mL) under the ice bath, and stirred for 5 minutes. Then 7-bromo-5-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)quinazolin-2,4(1H, 3H)-dione (2 g, 5.10 mmol) was added to the reaction solution, heated to 60° C., and stirred for 2 minutes.
  • Step 2 tert-butyl 3-(2-((7-bromo-1-(2-isopropyl-4-methylpyridin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-5-yl)oxy)ethyl)piperazin-1-carboxylate (1.5 g, 2.49 mmol) was dissolved in N,N-dimethylformamide (50 mL), 1,8-diazabicycloundec-7-ene (1.89 g, 12.45 mmol) and 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (3.89 g, 7.47 mmol) were added in sequence, and stirred for 2 hours at room temperature.
  • Step 3 tert-butyl 10-bromo-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-1,3,4,7,8,13,14,14a-octa hydro-2H-pyrazino[1′,2′:5,6][1,5]oxazolidine[4,3,2-de]quinazolin-2-carboxylat e (200 mg, 0.34 mmol), (5-methyl-1H-indazol-4-yl)boronic acid (90 mg, 0.51 mmol), chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (24 mg, 0.03 mmol), 2-bicyclohexylphosphin-2′,6′-dimethoxybiphenyl (14 mg, 0.03 mmol) and potassium
  • Step 4 trifluoroacetic acid (0.5 mL) was added to a solution of tert-butyl 8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-7-oxo-1,3,4,7,8,13,14,14a-octahydro-2H-pyrazino[1′,2′:5,6][1,5]oxazolidino[4,3,2-de]quinazolin-2-carboxylate (120 mg, 0.19 mmol) in dichloromethane (2 mL) under the ice bath, stirred for 2 hours at room temperature, and concentrated to obtain a yellow oily compound of 8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-1,3,4,13,14,14a-hexahydro-2H-pyrazino[1′,2′: 5,6]
  • Step 5 under the ice bath, triethylamine (191 mg, 1.89 mmol) was added to the above solution of the compound 8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-1,3,4,13,14,14a-hexahydro-2H-pyrazino[1′,2′: 5,6][1,5]oxazolidine[4,3,2-de]quinazolin-7 (8H)-one in dichloromethane (2 mL). After the reaction solution was clarified, acrylic anhydride (22 mg, 0.18 mmol) was dropped, and stirred for 5 minutes.
  • reaction solution was washed with the saturated sodium bicarbonate solution (5 mL), the organic phase was dried and concentrated, and then purified by Preparative HPLC (ammonium bicarbonate system) to obtain a white solid of Z22 (43.39 mg, purity: 100%, yield: 39%).
  • Step 1 tert-butyl (R)-2,3-dichloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (0.900 mg, 1.607 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (752 mg, 4.821 mmol), SPhos-Pd-G2 (115.7 mg, 0.1607 mmol), SPhos (66.0 mg, 0.1607 mmol), potassium phosphate (1.02 g, 4.821 mmol), dioxane (30 mL) and water (5.0 mL) were added to a single-neck flask, nitrogen was used for replacement for 3 times, and the reaction proceeded at 75° C.
  • Step 2 tert-butyl (5 aR)-3-chloro-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5] cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (0.660 g, 1.037 mmol) and methanol (5 mL) were added to a 100 mL single-neck round bottom flask, then dioxane hydrochloride solution (3.0 mL, 4M, 12.0 mmol) was added, and the reaction proceeded at room temperature for 2 hours.
  • Step 3 (5 aR)-3-chloro-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-5,5a,6,7,8,9-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-11 (12H)-one (0.720 g, 1.037 mmol) was dissolved in dichloromethane (20 mL), and triethylamine (1.04 g, 10.37 mmol) was added. The reaction was cooled to 0° C., acrylic anhydride (117 mg, 0.933 mmol) was dropped to the reaction solution.
  • Step 1 tert-butyl (S)-2-chloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (500 mg, 0.95 mmol), N-chlorosuccinimide (255 mg, 1.9 mmol) and acetonitrile (50 mL) were added to a round bottom flask. The reaction was stirred at 80° C. for 2 hours.
  • Step 2 tert-butyl (S)-2,3-dichloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxa-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthale n-7 (5H)-carboxylate (533 mg, 0.95 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (222 mg, 1.43 mmol), tetratriphenylphosphine palladium (109 mg, 0.095 mmol), sodium carbonate (302 mg, 2.85 mmol), 30 mL of dioxane and 6 mL of water were added to a 100 mL reaction flask.
  • Step 3 tert-butyl (5 aS)-3-chloro-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxa-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (309 mg, 0.48 mmol), 1 mL of methanol and 3 mL of hydrogen chloride/dioxane solution (4 M) were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour.
  • Step 4 (5 aS)-3-chloro-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-5,5a,6,7,8,9-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-11 (12H)-one (317 mg, 0.59 mmol), 10 mL of dichloromethane and triethylamine (597 mg, 5.9 mmol) were added to a round bottom flask.
  • the reaction was cooled to 0° C., and acrylic anhydride in dichloromethane (59 mg, 0.47 mmol, 0.5 mL) was dropped to the reaction solution.
  • the reaction was stirred at 0° C. for 10 minutes.
  • 40 mL of the saturated sodium bicarbonate aqueous solution was added to the reaction solution, and the reaction solution was extracted with 20 mL of dichloromethane for 3 times.
  • Step 1 tert-butyl (R)-2-chloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (200 mg, 0.3800 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (90.0 mg, 0.5769 mmol), SPhos-Pd-G2 (30 mg, 0.04167 mmol), SPhos (20 mg, 0.0487 mmol), potassium phosphate (0.240 g, 01.132 mmol), dioxane (10 mL) and water (2.0 mL) were added to a single-neck flask, nitrogen was used for replacement for 3 times, and the reaction proceeded at 120° C.
  • Step 2 Tert-butyl (R)-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (0.210 g, 0.3487 mmol) and methanol (5 mL) were added to a 100 mL single-neck round bottom flask, then dioxane hydrochloride solution (3.0 mL, 4M, 12.0 mmol) was added, and the reaction proceeded at room temperature for 2 hours.
  • Step 3 (R)-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-5,5a, 6,7,8,9-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-11 (12H)-one (0.234 g, 0.3487 mmol) was dissolved in dichloromethane (15 mL), triethylamine (3.0 mL, 21.62 mmol) was added. The reaction was cooled to 0° C., and acrylic anhydride (39.5 mg, 0.3138 mmol) was dropped to the reaction solution.
  • Example 26 Preparation of Compound Z26, Z26-1, Z26-2, Z26-2-1 and Z26-2-2
  • Step 1 Compound 4-bromo-2-fluoro-6-(((2-isopropyl-4-methylpyridin-3-yl)amino)benzonitrile (2.0 g, 5.6 mmol) was dissolved in acetonitrile (20 ml), then NCS (1.5 g, 2.0 eq) was added, the reaction proceeded at 80° C.
  • Step 2 4-bromo-3-chloro-2-fluoro-64 (2-isopropyl-4-methylpyridin-3-yl)amino)benzo nitrile (880 mg, 2.3 mmol) and 50 mL of dimethyl sulfoxide were added to a 250 mL three-necked round bottom flask, cooled to 0-5° C. under the ice bath, potassium carbonate (634 mg, 4.6 mmol) and hydrogen peroxide (938 mg, 30% aqueous solution, 8.28 mmol) were added, and the reaction proceeded overnight at this temperature. The completion of the reaction was detected by LCMS. The reaction solution was poured into about 15 mL of ice water, and a solid precipitated out.
  • Step 3 4-bromo-3-chloro-2-fluoro-64 (2-isopropyl-4-methylpyridin-3-yl)amino)benzamide (1.01 g, 2.49 mmol) and 20 mL of dry tetrahydrofuran were added to a 250 mL three-necked round bottom flask, cooled to 0-5° C. under the ice bath, sodium hydride (500 mg, 12.45 mmol) was added in batches, and the reaction proceeded at this temperature for 10 minutes. A suspension of CDI (806 mg, 4.98 mmol) in tetrahydrofuran (20 mL) was dropped to the above solution, and then the reaction proceeded at this temperature for 20 minutes.
  • CDI 806 mg, 4.98 mmol
  • Step 4 tert-butyl (S)-3-(hydroxymethyl)piperazin-1-carboxylate (557 mg, 2.58 mmol) was added to a suspension of 60% sodium hydride (412 mg, 10.32 mmol) in tetrahydrofuran (50 mL) at 0° C., the reaction proceeded at 0° C. for 30 minutes, a solution of 7-bromo-6-chloro-5-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)quinazolin-2,4 (1.1 g, 2.58 mmol) in tetrahydrofuran (20 mL) was dropped thereto. The reaction was stirred at 0° C. for 30 minutes.
  • Step 5 tert-butyl (S)-3-((((7-bromo-6-chloro-4-hydroxy-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydroquinazolin-5-yl)oxy)methyl)piperazin-1-carboxylate (1.04 g, 1.67 mmol), DBU (1.46 g, 10.02 mmol), PyBop (2.59 g, 6.87 mmol) dichloromethane (50 mL) were added to a round bottom flask. The reaction was stirred at room temperature for 30 minutes. The completion of the reaction was detected by LC-MS.
  • Step 6 tert-butyl (S)-10-bromo-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13 a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (806 mg, 1.34 mmol), (5-methyl-1H-indazol-4-yl)boronic acid (353 mg, 2.01 mmol), SPhos (55 mg, 0.134 mmol), SPhos-Pd-G2 (96 mg, 0.134 mmol), potassium phosphate (852 mg, 4.02 mmol), 60 mL of dioxane and 12 mL of water were added to a 100 mL reaction flask.
  • Step 7 tert-butyl (13aS)-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (395 mg, 0.6 mmol), 3 mL of trifluoroacetic acid and 6 mL of dichloromethane were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour.
  • Step 8 (13aS)-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (401 mg, 0.71 mmol), 6 mL of dichloromethane and triethylamine (718 mg, 7.1 mmol) were added to a round bottom flask.
  • Step 10 Compound Z26-2 (106 mg, 0.18 mmol) was resolved chirally (mobile phase: n-hexane-ethanol-40-60); column type: IB (250 mm*4.6 mm 5 um); flow rate: 1.0 ml/min; column temperature: 30° C.) to obtain: Compound Z26-2-1 (35 mg, retention time: 6.824 min, purity: 100%, de value: 100%).
  • ES-API: [M+H] + 611.2.
  • Compound Z26-2-2 ((31 mg, retention time: 9.384 min, purity: 100%, de value: 99%).
  • ES-API: [M+H] + 611.2.
  • Step 1 2,4,6-trichloronicotinic acid (8 g, 35.5 mmoL) was dissolved in 150 mL of dichloromethane and cooled to 0° C., and oxalyl chloride (9.3 ml, 106.6 mmol) was added. After 30 minutes for the completion of the dropping, DMF (0.5 ml) was dropped, the reaction rised to room temperature and proceeded for 1 hour. After the completion of the reaction, the reaction solution was concentrated and diluted with 150 mL of dichloromethane, cooled to 0° C., 8 mL of ammonia water was slowly dropped, and the reaction was stirred at room temperature for 2 h.
  • Step 2 2-isopropyl-4-methylpyridin-3-amine (4.4 g, 29.1 mmol) was dissolved in 80 mL of tetrahydrofuran, LiHMDS (106.4 ml, 1M) was dropped under the ice water bath under nitrogen protection, stirred for 30 minutes, 2,4,6-Trichloronicotinamide (6.5 g, 29.1 mmol) dissolved in 20 mL of tetrahydrofuran, was added to the above reaction solution, slowly rised to room temperature, and reacted for 2 hours, cooled to room temperature, and dilute hydrochloric acid was dropped to pH of 7-8.
  • LiHMDS 106.4 ml, 1M
  • 2,4,6-Trichloronicotinamide 6.5 g, 29.1 mmol
  • Step 3 4,6-dichloro-2-((2-isopropyl-4-methylpyridin-3-yl)amino)nicotinamide (1.77 g, 5.24 mmoL) was dissolved in 30 ml of tetrahydrofuran, 60% NaH (3 g, 15.72 mmol) was added under the ice water bath, stirred for 15 minutes, CDI (0.63 g, 7.86 mmol) was added, the reaction proceeded under the ice water bath for 1 hour, raw material disappeared, the reaction solution was poured into ice water, pH was adjusted to 5-6 with dilute hydrochloric acid.
  • Step 4 tert-butyl (S)-3-(hydroxymethyl)piperazin-1-carboxylate (1.02 g, 4.72 mmoL) was dissolved in tetrahydrofuran, 60% NaH (0.567 g, 14.2 mm1) was added under the ice water bath, stirred for 10 minutes, 5,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyridine[2,3-d]pyrimidin-2,4 (1H,3H)-dione (1.72 g, 4.72 mmoL) was added, and stirred for 20 minutes.
  • Step 5 tert-butyl (S)-3-((((7-chloro-4-hydroxy-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-5-yl)oxy)methyl)piperazin-1-formate (1.93 g, 3.54 mmoL) was dissolved in DMF, PyBOP (9.2 g, 17.7 mmoL) and DBU (2.69 g, 17.7 mmoL) was dropped under the ice water bath, and the reaction proceeded at room temperature for 2 hours. The completion of the reaction was detected.
  • Step 6 tert-butyl (S)-2-chloro-12-(2-ethyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (0.745 g, 1.42 mmoL), (5-methyl-1H-indazol-4-yl)boronic acid (500 mg, 2.84 mmol), Pd(PPh 3 ) 4 (164 mg, 0.142 mmol) and potassium carbonate (588 mg, 4.26 mmol) was dissolved in 8 mL of dioxane and 2 mL of water, nitrogen was used for replacement, the reaction proceeded at 120° C.
  • Step 7 tert-butyl (S)-12-(2-isopropyl-4-methylpyridin-3-yl)-2-(5-methyl-1H-indazol-4-yl)-11-ox o-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (371 mg, 0.6 mmoL) was dissolved in 10 mL of dichloromethane, 4 mL of trifluoroacetic acid was slowly dropped at room temperature, reacted for 5 hours, 10 mL of dichloromethane was added, concentrated under reduced pressure to obtain (S)-12-(2-isopropyl-4-methylpyridin-3-yl)-2-(5-methyl-1H-indazol-4-yl)-5,5a,6,7,8,9-hexahydro-4-oxo
  • Step 1 tert-butyl 10-bromo-8-cyclopropyl-7-oxo-1,3,4,7,8,13,14,14a-octahydro-2H-pyrazino[1′,2′:5,6][1,5]oxazolidine[4,3,2-de]quinazolin-2-carboxylate (100 mg, 0.2 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (48 mg, 0.3 mmol), chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (15 mg, 0.02 mmol), SPhos (8.4 mg, 0.02 mmol), potassium phosphate (130 mg, 0.6 mol), 10 mL of dioxane and 2 mL of water were added to a 100 mL three-necked
  • the system was replaced with the nitrogen for three times, and then protected with a nitrogen ball.
  • the reaction proceeded at 110° C. for 2 hours.
  • 30 mL of ethyl acetate was added to the reaction solution, the reaction solution was washed with 30 mL of the saturated brine for 3 times, dried and concentrated.
  • the crude product was purified by a fast silica gel column to obtain the target product: tert-butyl 8-cyclopropyl-10-(2-fluoro-6-hydroxyphenyl)-7-oxo-1,3,4,7,8,13,14,14a-octahydro-2H-pyrazino[1′,2′:5,6][1,5]oxazolidine[4,3,2-de]quinazolin-2-carboxylate (100 mg, yield: 93%).
  • ES-API: [M+H]+ 523.2.
  • Step 2 tert-butyl 8-cyclopropyl-10-(2-fluoro-6-hydroxyphenyl)-7-oxo-1,3,4,7,8,13,14,14a-octahydro-2H-pyrazino[1′,2′:5,6][1,5]oxazolidine[4,3,2-de]quinazolin-2-carboxylate (100 mg, 0.19 mol) was dissolved in dichloromethane (8 mL), and trifluoroacetic acid (2 mL) was added. The reaction was stirred at room temperature for 2 hours.
  • Step 3 8-cyclopropyl-10-(2-fluoro-6-hydroxyphenyl)-1,3,4,13,14,14a-hexahydro-2H-pyrazino[1′,2′:5,6][1,5]oxazolidine[4,3,2-de]quinazolin-7
  • 8H 8H-one (70 mg, 0.165 mmol) was dissolved in dichloromethane (15 mL), triethylamine (50 mg, 0.5 mmol) was added. The reaction was cooled to 0° C., and acrylic chloride (21 mg, 0.016 mol) was dropped to the reaction solution. The reaction was stirred at 0° C. for 15 minutes.
  • Example 29 Preparation of Compound Z29, Z29-1, Z29-2, Z29-3 and Z29-4
  • Step 1 tert-butyl (R)-10-bromo-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (149 mg, 0.25 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (59 mg, 0.38 mmol), SPhos (10 mg, 0.025 mmol), SPhos-Pd-G2 (18 mg, 0.025 mmol), potassium phosphate (159 mg, 0.75 mmol), 60 mL of dioxane and 12 mL of water were added to a 100 mL reaction flask.
  • the reaction was stirred at 115° C. for 2 hours under nitrogen protection, and the reaction stopped. 50 mL of water was added to the reaction solution. The reaction solution was extracted with 50 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • Step 2 Tert-butyl (13aR)-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (111 mg, 0.18 mmol), 3 mL of trifluoroacetic acid and 6 mL of dichloromethane were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour. The completion of the reaction was detected by LC-MS.
  • Step 3 (13aR)-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-8-(2-isopropyl-4-methylpyridin-3-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (121 mg, 0.21 mmol), 6 mL of dichloromethane and triethylamine (212 mg, 2.1 mmol) were added to a round bottom flask.
  • Example 30 Preparation of Compound Z30, Z30-1, Z30-2, Z30-2-1 and Z30-2-2
  • Step 1 tert-butyl (R)-10-bromo-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (500 mg, 0.83 mmol), (5-methyl-1H-indazol-4-yl)boronic acid (224 mg, 1.27 mmol), SPhos (34 mg, 0.084 mmol), SPhos-Pd-G2 (60 mg, 0.084 mmol), potassium phosphate (535 mg, 2.52 mmol), 60 mL of dioxane and 12 mL of water were added to a 100 mL reaction flask.
  • the reaction was stirred at 115° C. for 2 hours under nitrogen protection, and the reaction stopped. 50 mL of water was added to the reaction solution. The reaction solution was extracted with 50 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • Step 2 tert-butyl (13aR)-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (418 mg, 0.64 mmol), 3 mL of trifluoroacetic acid and 6 mL of dichloromethane were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour.
  • Step 3 (13aR)-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (501 mg, 0.9 mmol), 6 mL of dichloromethane and triethylamine (450 mg, 4.5 mmol) were added to a round bottom flask.
  • ES-API: [M+H] + 611.2; and Compound Z30-2-2 ((31 mg, retention time: 4.861 min, purity: 100%, de value: 98%).
  • ES-API: [M+H] + 611.2.
  • Step 1 4-bromo-2,6-difluorobenzonitrile (10 g, 45.87 mmol) was added to isopropanol (200 mL), then 2-methylprop-1-amine (5 g, 68.8 mmol) was added, and the reaction solution was heated to 50° C. to react for two hours. The completion of the reaction was detected by LCMS, iPrOH was spin-dried, 100 mL of water was added.
  • ES-API: [M+1] + 271.0, 273.0.
  • Step 2 4-bromo-2-fluoro-6-(isobutylamino)benzonitrile (10 g, 37 mmol), was dissolved in isopropanol (100 mL), NCS (5.4 g, 40.7 mmol) was added, the reaction solution was heated to 50° C. to react for 3 hours.
  • Step 3 4-bromo-3-chloro-2-fluoro-6-(isobutylamino)benzonitrile (3.3 g, 10.8 mmol) was dissolved in DMSO (50 mL), then potassium carbonate (2.8 g, 20.4 mmol) was added, hydrogen peroxide (1.3 g, 37 mmol) was slowly dropped at room temperature, the reaction solution was stirred for 3 hours at room temperature. The completion of the reaction was detected by LCMS. Sodium sulfite (5 g, 39.7 mmol) was added and stirred for 30 minutes, and then water (100 mL) was added.
  • ES-API: [M+1] + 322.9, 324.9.
  • Step 4 NaH (1.6 g, 66 mmol) was dissolved in tetrahydrofuran (40 mL) and cooled to 0° C., then 4-bromo-3-chloro-2-fluoro-6-(isobutylamino)benzamide (2.1 g, 6.6 mmol) dissolved in 10 mL of tetrahydrofuran was slowly dropped to the reaction solution, stirred for 1 hour at 0° C., then N,N′-carbonyl diimidazole (1.4 g, 8.58 mmol) dissolved in 10 mL of tetrahydrofuran was slowly dropped to the reaction solution at 0° C., then naturally warmed up to room temperature, stirred for 30 minutes.
  • ES-API: [M+1] + 348.9, 350.9.
  • Step 6 Tert-butyl (S)-3-(((7-bromo-6-chloro-4-hydroxy-1-isobutyl-2-oxo-1,2-dihydroquinazolin-5-yl)oxy)methyl)piperazin-1-carboxylate (1.2 g, 2.2 mmol) was dissolved in N,N-dimethylformamide (20 mL), 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (3.45 g, 6.6 mmol) was added, 1,8-diazabicyclo[5.4.0]undec-7-ene (1.67 g, 11 mmol) was slowly dropped under the ice bath, then heated to room temperature and stirred for 2 hours, the detection of LC-MS showed the completion of the reaction, 30 mL of water was added, extracted with ethyl acetate (30 mL*3), the extracted organic phase was spin-dried to obtain the crude product, and the crude
  • Step 7 tert-butyl (S)-10-bromo-11-chloro-8-isobutyl-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′: 3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (530 mg, 1.0 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (312 mg, 2.0 mmol), tripotassium phosphate (636 mg, 6.0 mmol), chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (72 mg, 0.1 mmol), 2-bicyclohexylphosphin-2′,4′,6′-triisopropylbiphenyl(
  • Step 8 tert-butyl (13aS)-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-8-isobutyl-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (370 mg, 0.67 mmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (2 mL) was added, and reacted at room temperature for 1 hour, spin-dried to obtain a yellow oily crude product: (13aS)-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-8-isobutyl-1,2,3,4,13,13a hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8
  • Step 9 (13aS)-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-8-isobutyl1,2,3,4,13,13a hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (300 mg, 0.655 mmol), and triethylamine (2 mL) was dissolved in dichloromethane (5 mL), cooled to 0° C., acrylic anhydride (75 mg, 0.59 mmol) was added, and reacted at 0° C. for 0.5 hour.
  • ES-API: [M+1] + 513.1.
  • Step 1 4-bromo-2,6-difluorobenzonitrile (10 g, 45.87 mmol) and tetrahydro-2H-pyran-4-amine (13.9 g, 137.6 mmol) was dissolved in i-PrOH (150 mL), and reacted at 70° C. for 16 hours. The solvent was concentrated to obtain a crude product, the crude product was washed with water (3 ⁇ 100 mL) to obtain 4-bromo-2-fluoro-6-((tetrahydro-2H-pyran-4-yl)amino)benzonitrile (13 g, 43.48 mmol, yield: 94.9%), a white solid.
  • ES-API: [M+H] + 299.0.
  • Step 2 4-bromo-2-fluoro-6-((tetrahydro-2H-pyran-4-yl)amino)benzonitrile (9 g, 30.1 mmol) was dissolved in DMF (80 mL), 1-chloropyrrolidin-2,5-dione (4.82 g, 31.62 mmol) was added in batches at 70° C. The resulting mixture reacted at 80° C. for 1 hour. After cooling to room temperature, water (50 mL) was added to form a solid.
  • Step 3 4-bromo-3-chloro-2-fluoro-6-((tetrahydro-2H-pyran-4-yl)amino)benzonitrile (7 g, 20.99 mmol) was dissolved in DMSO (100 mL), then potassium carbonate (5.82 g, 42.2 mmol) was added, and finally hydrogen peroxide (8.61 g, 75.95 mmol) was dropped at 0° C. Then, the resulting mixture was stirred at room temperature for 2 hours. The mixture was poured into ice water (50 mL), and extracted with ethyl acetate (3 ⁇ 200 mL).
  • Step 4 4-bromo-3-chloro-2-fluoro-6-((tetrahydro-2H-pyran-4-yl)amino)benzamide (3.6 g, 10.24 mmol) was dissolved in tetrahydrofuran (50 mL), NaH (2.5 g, 61.44 mmol) was added at 0° C. in batches, and reacted at 0° C. for 0.5 hour. Then a solution of CDI (2.5 g, 15.36 mmol) in tetrahydrofuran (10 mL) was dropped at 0° C., and finally the resulting mixture was stirred at 0° C. for 2 hours.
  • CDI 2.5 g, 15.36 mmol
  • Step 5 NaH (1.8 g, 45 mmol) was added to a solution of tert-butyl (S)-3-(hydroxymethyl)piperazin-1-formate (2.92 g, 13.5 mmol) in THF (60 mL) at 0° C. in batches, the resulting mixture was stirred at 0° C. for 0.5 hour. Then, 7-bromo-6-chloro-5-fluoro-4-hydroxy-1-(tetrahydro-2H-pyran-4-yl)quinazolin-2 (1H)-one (3.4 g, 9 mmol) was added at 0° C., and the resulting mixture was stirred at 0° C. to room temperature for 2 hours.
  • Step 6 tert-butyl (S)-3-(((7-bromo-6-chloro-4-hydroxy-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1,2-dihydroquinazolin-5-yl)oxy)methyl)piperazin-1-carboxylate (2 g, 3.48 mmol) was dissolved in (30 mL), then carter condensing agent (3.86 g, 8.71 mmol) was added. 1,8-diazabicycloundec-7-ene (2.65 g, 17.42 mmol) was dropped at 0° C., and the resulting mixture was stirred at 0° C. to room temperature for 2 hours.
  • Step 7 tert-butyl (S)-10-bromo-11-chloro-7-oxo-8-(tetrahydro-2H-pyran-4-yl)-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (1.3 g, 2.34 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (548 mg, 3.51 mmol), potassium phosphate (1.5 g, 7.02 mmol), SPhos (192 mg, 0.468 mmol) and SPhos-Pd-G2 (166 mg, 0.234 mmol) was dissolved in dioxane/water (20 mL, 5:1) under nitrogen protection, and reacted at 110° C.
  • Step 8 tert-butyl (13aS)-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-7-oxo-8-(tetrahydro-2H-pyran-4-yl)-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (500 mg, 0.85 mmol) was dissolved in dichloromethane (6.0 mL) and trifluoroacetic acid (2.0 mL), and reacted at room temperature for 1 hour. The solvent was concentrated to obtain a crude product (611 mg, a brown oil), it can be used in the next step without further purification.
  • ES-API: [M+H] + 487.1.
  • Step 9 tert-butyl (13aS)-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-7-oxo-8-(tetrahydro-2H-pyran-4-yl)-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (414 mg, 0.85 mmol) and triethylamine (430 mg, 4.25 mmol) was dissolved in dichloromethane (10 mL).
  • Step 1 tert-butyl (S)-10-bromo-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13 a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (1.1 g, 1.82 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)pyrid-2-amine (600 mg, 2.73 mmol), [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (133 mg, 0.182 mmol), potassium acetate (535 mg, 5.46 mmol) was dissolved in dioxane/water (15/3 mL), heated to 100° C.
  • Step 2 tert-butyl (S)-10-(2-aminopyridin-3-yl)-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxheptidine[5,6,7-de]quinazolin-2 (1H)-carboxylate (1.5 g, 1.82 mmol) was dissolved in dichloromethane (10 mL), trifluoroacetic acid (5 mL) was added, the reaction solution was stirred at room temperature for 0.5 hour, and the solvent was concentrated to dryness under reduced pressure to obtain the crude product: (S)-10-(2-aminopyrid-3-yl)-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,
  • Step 3 (S)-10-(2-aminopyridin-3-yl)-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (1.5 g, 1.82 mmol) was dissolved in dichloromethane (100 mL), the reaction solution was cooled to 0° C., triethylamine (552 mg, 5.46 mmol) was added, acrylic anhydride (183 mg, 1.46 mmol) was dropped, and reacted at 0° C.
  • Step 1 tert-butyl (S)-10-bromo-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13 a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (60 mg, 0.1 mmol), 3-fluoro-2-(tributyltinalkyl)pyridine (58 mg, 0.15 mmol), tetra(triphenylphosphine)palladium (12 mg, 0.01 mmol), lithium chloride (13 mg, 0.3 mmol), cuprous iodide (2 mg, 0.01 mmol) was dissolved in dioxane (1.5 mL), heated to 100° C.
  • Steps 2-3 Compound Z35 was prepared according to the corresponding steps of Example 34.
  • ES-API: [M+H] + 575.2.
  • Step 1 tert-butyl (S)-2-chloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (900 mg, 1.7 mmol), 2-fluoro-6-hydroxyphenylboronic acid (400 mg, 2.6 mmol), SPhos (53 mg, 0.13 mmol), SPhos-Pd-G2 (98 mg, 0.13 mmol), potassium phosphate (1.1 g, 5.1 mmol), 12 mL of dioxane and 3 mL of water were added to a reaction flask.
  • the reaction was stirred under a 120° C. oil bath for 1 hour under nitrogen protection. 50 mL of water was added to the reaction solution. The reaction solution was extracted with 30 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • Step 2 tert-butyl (S)-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-11-ox o-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (1 g, 1.66 mmol), 5 mL of methanol and 5 mL of hydrogen chloride/dioxane solution (4 M) were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour. The completion of the reaction was detected by LC-MS.
  • Step 3 (S)-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-5,5a, 6,7,8,9-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-11 (12H)-one (835 mg, 1.66 mmol), 15 mL of dichloromethane and triethylamine (545 mg, 5.4 mmol) were added to a round bottom flask. The reaction was cooled to 0° C., and acrylic anhydride in dichloromethane (188 mg, 1.49 mmol) was dropped to the reaction solution.
  • Compound Z37 was prepared with 2-cyclopropylmethyl-1-amine as the raw material according to the method of Example 32.
  • Step 1 tert-butyl (S)-10-bromo-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13 a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (1.1 g, 1.82 mmol), (1-methyl-2-oxo-1,2-dihydropyridin-3-yl)boronic acid (418 g, 2.73 mmol), [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride (133 mg, 0.182 mmol), potassium acetate (535 mg, 5.46 mmol) was dissolved in dioxane/water (15/5 mL), heated to 100° C.
  • Steps 2-3 Compound Z38 was prepared according to the corresponding steps of Example 34.
  • ES-API: [M+H] + 587.2.
  • Step 1 sodium bis(trimethylsilyl)amide (42 mL) was dropped to a mixed solution of 4-bromo-2,6-difluorobenzonitrile (8.0 g, 36.70 mmol) and 2-isopropylpyridin-3-amine (5.0 g, 36.70 mmol) in tetrahydrofuran (50 mL) at ⁇ 65° C., and maintained for 0.5 hour at ⁇ 60° C. Tetrahydrofuran (100 mL) was added when the temperature rised to ⁇ 50° C. Then the mixture slowly rised to room temperature and stirred for 3 hours. The reaction mixture was poured into ice water (20 mL) and extracted with dichloromethane (3 ⁇ 100 mL).
  • Step 2 acetonitrile (75 mL) and deionized water (225 mL) were added to a 500 mL round bottom flask containing 4-bromo-2-fluoro-6-((2-isopropylpyridin-3-yl)amino)benzonitrile (10.0 g, 29.92 mmol), sodium chloride (3.5 g, 59.85 mmol), potassium peroxymonosulfonate (13.79 g, 22.44 mmol). The reaction mixture was heated to 70° C. in an air atmosphere overnight, potassium peroxymonosulfonate (10.0 g, 16.27 mmol) was additional added, then heated to 80° C. and continued to react for 6 hours.
  • the mixture was poured into ice water (150 mL) and extracted with dichloromethane (3 ⁇ 100 mL). The organic phases was combined, washed with the saturated ammonium chloride (3 ⁇ 50 mL) and the saturated brine (3 ⁇ 50 mL), dried with anhydrous sodium sulfate. The solvent was spin-evaporated to be removed.
  • the mixture was poured into ice water (100 mL) and extracted with dichloromethane (3 ⁇ 100 mL). The organic phases was combined, washed with the saturated ammonium chloride (3 ⁇ 30 mL) and the saturated brine (3 ⁇ 50 mL), dried with anhydrous sodium sulfate. The solvent was spin-evaporated to be removed.
  • Step 6 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (1.54 g, 2.96 mmol) was added to a mixed solution of tert-butyl (S)-3-(((7-bromo-6-chloro-4-hydroxy-1-(2-isopropylpyridin-3-yl)-2-oxo-1,2-dihydroquinazolin-5-yl)oxy)methyl)piperazin-1-carboxylate (0.6 g, 0.985 mmol in N,N′-dimethylformamide (10 mL) at 0° C., and then 1,8-diazabicyclo[5.4.0]undec-7-ene (0.75 g, 4.93 mmol) was dropped, and after addition was completed, transferred to room temperature immediately and reacted for 1 hour.
  • the mixture was poured into ice water (100 mL) and extracted with ethyl acetate (3 ⁇ 30 mL). The organic phases was combined, washed with the saturated ammonium chloride (3 ⁇ 30 mL) and the saturated brine (3 ⁇ 50 mL), dried with anhydrous sodium sulfate. The solvent was spin-evaporated to be removed.
  • Step 7 tetratriphenylphosphine palladium (0.051 g, 0.044 mmol) was added to a mixed solution of tert-butyl (S)-10-bromo-11-chloro-8-(2-isopropylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (0.26 g, 0.44 mmol), (5-methyl-1H-indazol-4-yl)boronic acid (0.155 g, 0.88 mmol) and sodium carbonate (0.117 g, 1.1 mmol) in 1,4-dioxane (3 mL) and water (0.75 mL).
  • the resulting mixture was heated to 110° C. and reacted for 1.5 hours under argon atmosphere. After cooling to room temperature, The reaction mixture was extracted with dichloromethane (3 ⁇ 150 mL). The organic phases was combined, washed with water (1 ⁇ 50 mL) and the saturated brine (3 ⁇ 50 mL), dried with anhydrous sodium sulfate. The solvent was spin-evaporated to be removed.
  • Step 8 trifluoroacetic acid (1 mL) was added to a solution of tert-butyl (13aS)-11-chloro-8-(2-isopropylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (40 mg, 0.062 mmol) in dichloromethane (2 mL). The resulting mixture was stirred at room temperature for 30 minutes.
  • the pH of the reaction mixture was adjusted to 8 with 1M sodium bicarbonate.
  • the reaction mixture was extracted with dichloromethane (3 ⁇ 20 mL). The organic phases was combined, washed with the saturated brine (3 ⁇ 20 mL), dried with anhydrous sodium sulfate.
  • Step 9 triethylamine (0.056 g, 0.55 mmol) was added to a solution of (13aS)-11-chloro-8-(2-isopropylpyridin-3-yl)-10-(5-methyl-1H-indazol-4-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-one (30 mg, 0.055 mmol) in dichloromethane (2 mL). The mixture was cooled to 0° C. Acrylic anhydride (6.98 mg, 0.055 mmol) was added at 0° C.
  • Step 1 tert-butyl (R)-10-bromo-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (1.0 g, 1.65 mmol), (1-methyl-2-oxo-1,2-dihydropyridin-3-yl)boronic acid (379 mg, 2.48 mmol), potassium acetate (485 mg, 4.95 mmol) and Pd (dppf)Cl 2 (121 mg, 0.165 mmol) dissolved in 1,4-dioxane/water (15 mL, 5:1) was added in sequence to a 100 mL round bottom flask, and reacted at 110° C.
  • Step 2 tert-butyl (R)-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-10-(1-methyl-2-oxo-1,2-di hydropyridin-3-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (1.0 g, 1.58 mmol was dissolved in dichloromethane (12.0 mL), then trifluoroacetic acid (4.0 mL) was added, and reacted at room temperature for 1 hour.
  • Step 3 (R)-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-10-(1-methyl-2-oxo-1,2-di hydropyridin-3-yl)-1,2,3,4,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-1-one (842 mg, 1.58 mmol) was dissolved in dichloromethane (10 mL), and triethylamine (479 mg, 4.74 mmol) was added at 0° C.
  • Step 1 tert-butyl (S)-10-bromo-11-chloro-8-(2-isopropyl-4-methylpyridin-3-yl)-7-oxo-3,4,7,8,13,13 a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (800 mg, 1.32 mmol) was dissolved in toluene (10 mL), 1-methyl-6-(tributyltinalkyl)pyridin-2 (1H)-one (631 mg, 1.59 mmol) and tetra(triphenylphosphine)palladium (114 mg, 0.132 mmol) were added, and reacted at 100° C.
  • Step 1 4-bromo-2,6-difluorobenzonitrile (540 mg, 2.48 mmol) was dissolved in tetrahydrofuran (4 mL), and cooled to ⁇ 70° C., sodium bis(trimethylsilyl)amide (2.3 mL, 4.5 mmol) was dropped, and after stirring for 30 minutes at ⁇ 70° C., a solution of 4-isopropyl-6-methylpyrimidin-5-amine in tetrahydrofuran (4 mL) was dropped. The reaction solution gradually rised to room temperature, and stirred overnight. The reaction was quenched with ammonium chloride aqueous solution.
  • Step 3 4-bromo-3-chloro-2-fluoro-6-((4-isopropyl-6-methylpyrimidin-5-yl)amino)benzonitrile (620 mg, 1.61 mmol) was dissolved in dimethyl sulfoxide (8 mL), potassium carbonate (1.1 g, 8.07 mmol) was added, cooled to 0° C., hydrogen peroxide was dropped (659 mg, 5.81 mmol). The reaction rised to room temperature, and stirred for 5 hours. The reaction solution was quenched with sodium sulfite aqueous solution.
  • Step 4 sodium hydride (497 mg, 12.4 mmol) was suspended in tetrahydrofuran (5 mL), cooled to ⁇ 10° C., a solution of 4-bromo-3-chloro-2-fluoro-6-((4-isopropyl-6-methylpyrimidin-5-yl)amino)benzamide (500 mg, 1.24 mmol) in tetrahydrofuran (5 mL) was dropped, and after stirring for 20 minutes, a solution of carbonyl diimidazole in tetrahydrofuran (5 mL) was dropped. The reaction solution was stirred at ⁇ 10° C. for 1 hour.
  • reaction solution cooled to ⁇ 30° C., and the pH was adjusted to 2-3 with 0.5M hydrochloric acid solution.
  • ES-API: [M+1] + 429.0.
  • Step 5 7-bromo-6-chloro-5-fluoro-4-hydroxy-1-(4-isopropyl-6-methylpyrimidin-5-yl) quinazolin-2 (1H)-one (240 mg, 0.56 mmol) and tert-butyl (S)-3-(hydroxymethyl)piperazin-1-carboxylate (182 mg, 0.84 mmol) was dissolved in tetrahydrofuran (4 mL), cooled to 0° C., sodium hydride (112 mg, 2.8 mmol) was added, rised to room temperature, and stirred for 1 hour. The reaction solution was quenched with water.
  • Step 6 tert-butyl (S)-3-(((7-bromo-6-chloro-4-hydroxy-1-(4-isopropyl-6-methylpyrimidin-5-yl)-2-oxo-1,2-dihydroquinazolin-5-yl)oxy)methyl)piperazin-1-carboxylate (180 mg, 0.29 mmol) was dissolved in acetonitrile (9 mL), N,N-diisopropylethylamine (112 mg, 0.86 mmol) and phosphorus oxychloride (66 mg, 0.43 mmol) were added, heated to 80° C., and stirred for 2 hours. The reaction solution was quenched with sodium bicarbonate aqueous solution.
  • Step 7 tert-butyl (S)-10-bromo-11-chloro-8-(4-isopropyl-6-methylpyrimidin-5-yl)-7-oxo-3,4,7,8,13,13a-hexahydropyrazino[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-2 (1H)-carboxylate (150 mg, 0.25 mmol) was dissolved in dioxane (2 mL) and water (0.4 mL), (5-methyl-1H-indazol-4-yl)boronic acid (87 mg, 0.49 mmol), 2-dicyclohexylphosphino-2′,6′-dimethoxy-biphenyl (10 mg, 0.025 mmol), tris(dibenzylideneacetone)dipalladium (23 mg, 0.025 mmol) and potassium phosphate (157 mg, 0.74 mmol) were added, and
  • Step 8 Compound Z45-c (20 mg, 0.03 mmol) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (0.5 mL) was added and reacted at room temperature for 1 hour, spin-dried to obtain a yellow oily crude product: (13aS)-11-chloro-8-(4-isopropyl-6-methylpyrimidin-5-yl)-10-(5-methyl-1H-indazol-4-yl)-1,2,3,4,13,13a-hexahydropyrazine[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-on e, a crude product (17 mg, yield: 100%).
  • Step 9 (13aS)-11-chloro-8-(4-isopropyl-6-methylpyrimidin-5-yl)-10-(5-methyl-1H-indazol-4-yl)-1,2,3,4,13,13a-hexahydropyrazine[2′,1′:3,4][1,4]oxazepine[5,6,7-de]quinazolin-7 (8H)-on e (17 mg, 0.03 mmol), and triethylamine (0.5 mL) was dissolved in dichloromethane (2 mL), cooled to 0° C., acrylic anhydride (3 mg, 0.027 mmol) was added, and reacted at 0° C. for 0.5 hour.
  • reaction solution was extracted with 10 mL of water and dichloromethane (10 mL*3), the extracted organic phase was spin-dried to obtain the crude product, the crude product was prepared and purified (chromatographic column: Ultimate XB-C18,50*250 mm, 10 um; elution system: acetonitrile/water, 40 minutes from 10% to 90%; monitoring wavelength 210 nm; flow rate 80 mL/min), freeze-dried to obtain Compound Z45-1 (4 mg, yield: 20%).
  • ES-API: [M+1] + 611.2.
  • Steps 12-13 With Compound Z45-a as raw material, the method of steps 8-9 in Example 45 was referred to obtain Compound Z45-4 (a white solid, 4.2 mg).
  • ES-API: [M+1] + 611.2.
  • Step 1 tert-butyl (S)-2,3-dichloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5 ⁇ ,6,8,9,11,12hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthale n-7 (5H)-carboxylate (300 mg, 0.54 mmol), (2-fluorophenyl)boronic acid (227 mg, 1.62 mmol), tetratriphenylphosphine palladium (62 mg, 0.054 mmol), sodium carbonate (172 mg, 1.62 mmol), 50 mL of dioxane and 10 mL of water were added to a 100 mL reaction flask.
  • the reaction was stirred at 65° C. for 3 hours under nitrogen protection, and the reaction stopped. 30 mL of water was added to the reaction solution. The reaction solution was extracted with 30 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • Compound Z47 was prepared with (2,3-difluorophenyl)boronic acid as the raw material according to the method of Example 46.
  • ES-API: [M+H] + 594.2.
  • ES-API: [M+H] + 594.2;
  • Compound Z49 was prepared with (2,4-difluorophenyl)boronic acid as the raw material according to the method of Example 46.
  • ES-API: [M+H] + 594.2.
  • ES-API: [M+H] + 594.1.
  • Step 1 tert-butyl (S)-2,3-dichloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (200 mg, 0.36 mmol), (2,3-difluoro-6-methoxyphenyl)boronic acid (200 mg, 1.07 mmol), chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (28 mg, 0.04 mmol), 2-bicyclohexylphosphin-2′,6′-dimethoxybiphenyl (16 mg
  • Step 2 17% boron tribromide in dichloromethane solution (2 mL) was added to a solution of tert-butyl (S)-3-chloro-2-(2,3-difluoro-6-methoxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (100 mg, 0.15 mmol) in dichloromethane (2 mL) solution under the ice bath, and stirred at room temperature for 3 hours.
  • Step 3 N,N-diisopropylethylamine (58 mg, 0.45 mmol) was added to a solution of (S)-3-chloro-2-(2,3-difluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-5,5a,6,7,8,9-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5] cyclohepta[1,2,3-de]naphthalen-11 (12H)-one (83 mg, 0.15 mmol) in dichloromethane (2 mL) under the ice bath.
  • Compound Z57 was prepared with (2-fluoro-3-(trifluoromethyl)phenyl)boronic acid as the raw material according to the method of Example 46.
  • ES-API: [M+H] + 644.2.
  • ES-API: [M+H] + 644.2.
  • Step 1 tert-butyl (R)-2-chloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo5 ⁇ ,6,8,9,11,12hexa hydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (0.43 g, 0.82 mmol), N-bromosuccinimide (292 mg, 1.64 mmol) and acetonitrile (5 mL) were added to a round bottom flask. The reaction was stirred at 70° C. for 2 hours.
  • Step 2 tert-butyl (R)-3-bromo-2-chloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (180 mg, 0.30 mmol), 2,4,6-trimethyl-1,3,5,2,4,6-trioxytriborane (113 mg, 0.90 mmol), Pd(dppf)Cl 2 (22 mg, 0.03 mmol), potassium phosphate (191 mg, 0.9 mmol), 5 mL of dioxane and 1 mL of water were added to a reaction flask.
  • the reaction was stirred under a 70° C. oil bath for 12 hours, and the reaction stopped. 20 mL of water was added to the reaction solution. The reaction solution was extracted with 20 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • Step 3 tert-butyl (R)-2-chloro-12-(2-isopropyl-4-methylpyridin-3-yl)-3-methyl-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (110 mg, 0.20 mmol), 2-fluoro-6-hydroxyphenylboronic acid (156 mg, 1.0 mmol), SPhos (8 mg, 0.02 mmol), SPhos-Pd-G2 (14 mg, 0.02 mmol), potassium phosphate (127 mg, 0.6 mmol), 5 mL of dioxane and 1 mL of water were added to a reaction flask.
  • the reaction was stirred under a 80° C. oil bath for 6 hours, and the reaction stopped. 20 mL of water was added to the reaction solution. The reaction solution was extracted with 20 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • Step 4 tert-butyl (5 aR)-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-3-methyl-11-oxo5 ⁇ ,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5] cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (55 mg, 0.089 mmol), 1 mL of methanol and 4 M hydrogen chloride/dioxane solution (3 mL) were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour.
  • Step 5 (5 aR)-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-3-methyl-5,5a,6,7,8,9-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cycloheptan[1,2,3-de]naphthalen-11 (12H)-one (46 mg, 0.089 mmol), 3 mL of dichloromethane and triethylamine (27 mg, 0.27 mmol) were added to a 50 mL round bottom flask.
  • the reaction was cooled to 0° C., and acrylic anhydride in dichloromethane (31 mg, 0.25 mmol, 0.5 mL) was dropped to the reaction solution.
  • the reaction was stirred at 0° C. for 10 minutes.
  • 20 mL of the saturated sodium bicarbonate aqueous solution was added to the reaction solution, and the reaction solution was extracted with 10 mL of dichloromethane for 3 times.
  • the organic phase was dried and concentrated.
  • the crude product was purified by Preparative HPLC to obtain Z72 (17.88 mg, yield of two steps: 35%), a white solid.
  • Step 1 tert-butyl (R)-2-chloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo5 ⁇ ,6,8,9,11,12hexa hydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (1.1 g, 2.09 mmol), Selectfluor (3.69 g, 10.4 mmol) and 50 mL of acetonitrile were added to a round bottom flask. The reaction was stirred at 80° C. for 2 hours. The reaction solution was poured into ice water.
  • Steps 2-4 Compound Z73 was prepared according to the method of steps 3-5 in Example 72.
  • ES-API: [M+H] + 575.2.
  • Step 1 tert-butyl (R)-2-chloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (1 g, 1.9 mmol) and a solution of N-chlorosuccinimide (507 mg, 3.8 mmol) in acetonitrile (20 mL) were stirred at 80° C. for 3 hours under nitrogen protection.
  • Step 2 tert-butyl (R)-2,3-dichloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (300 mg, 0.53 mmol), 2-fluoro-6-methoxyphenylboronic acid (270 mg, 1.60 mmol), [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride (39 mg, 0.05 mmol) and a mixed solution of potassium carbonate (220 mg, 1.60 mmol) in 1,4-dioxane (5 mL) and water (1 mL) reacted under a 120° C.
  • Step 3 tert-butyl (5aR)-3-chloro-2-(2-fluoro-6-methoxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5] cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (200 mg, 0.3 mmol), potassium vinyltrifluoroborate (120 mg, 0.9 mmol), chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (20 mg, 0.03 mmol), 2-bicyclohexylphosphin-2′,6′-dimethoxybiphenyl (12 mg
  • Step 4 17% boron tribromide in dichloromethane solution (2 mL) was added to a solution of tert-butyl (5aR)-2-(2-fluoro-6-methoxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-3-vinyl-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (120 mg, 0.19 mmol) in dichloromethane (2 mL) under the ice bath, and stirred at room temperature for 3 hours.
  • Step 5 N,N-diisopropylethylamine (74 mg, 0.57 mmol) was added to a solution of (5 aR)-2-(2-fluoro-6-hydroxyphenyl)-12-(2-isopropyl-4-methylpyridin-3-yl)-3-vinyl-5,5a,6,7,8,9-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-11 (12H)-one (100 mg, 0.19 mmol) in dichloromethane (2 mL) under the ice bath.
  • ES-API: [M+H] + 593.1.
  • Compound Z77 was prepared with (2,3-difluorophenyl)boronic acid as the raw material according to the method of Example 46.
  • ES-API: [M+H] + 593.1.
  • Compound Z87 was prepared with 2-fluorophenylboronic acid as the raw material according to the method of Example 46.
  • ES-API: [M+H] + 575.2.
  • Compound Z88 was prepared with (2-fluoro-6-hydroxyphenyl)boronic acid as the raw material according to the method of Example 46.
  • ES-API: [M+H] + 592.2.
  • Step 1 morpholine (17.4 mg, 0.2 mmol) and 60% NaH (12 mg, 0.3 mmol) was dissolved in dry DMF (3 ml) under the ice water bath, stirred for 10 minutes, tert-butyl (R)-2,3-dichloro-12-(2-isopropyl-4-methylpyridin-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (56 mg, 0.1 mmoL) was slowly added, the reaction rised to room temperature and proceeded for 1 hour.
  • Steps 2-3 Compound Z89 was prepared according to the corresponding steps of Example 34.
  • ES-API: [M+H] + 566.2.
  • Compound Z91 was prepared with (3-chloro-2-fluorophenyl)boronic acid as the raw material according to the method of Example 46.
  • ES-API: [M+H] + 610.3.
  • Compound Z91 (274 mg, 0.45 mmol) was resolved chirally (mobile phase: n-hexane-ethanol-40-60); column type: IG (250 mm*4.6 mm 5 um); flow rate: 1.0 ml/min; column temperature: 30° C.) to obtain: Compound Z91-1 (103 mg, retention time: 8.228 min, purity: 99%, de value: 99%).
  • ES-API: [M+H] + 610.3.
  • Step 1 4-isopropyl-2-methylpyridin-3-amine (1 g, 6.7 mmol) and 30 mL of tetrahydrofuran were added to a 250 mL round bottom flask. After the system cooling to 0° C., sodium bis(trimethylsilyl)amide (8.3 mL, 2 M in tetrahydrofuran, 16.5 mmol) was dropped to the reaction solution. After the completion of the dropping, the reaction was stirred at 0° C. for 10 minutes. and then a solution of 4,6-dichloro-2-fluoronicotinamide (1.4 g, 6.7 mmol) in tetrahydrofuran (30 mL) was dropped to the reaction solution.
  • Step 2 4,6-dichloro-2-(((4-isopropyl-2-methylpyridin-3-yl)amino)nicotinamide (2.1 g, 6.0 mmol) and 80 mL of dry tetrahydrofuran were added to a 250 mL three-necked round bottom flask, cooled to 0-5° C. under the ice bath, sodium hydride (1.2 g, 30 mmol) was added in batches, and the reaction proceeded at this temperature for 10 minutes. A suspension of CDI (1.9 g, 12 mmol) in tetrahydrofuran (40 mL) was dropped to the above solution, and then the reaction proceeded at this temperature for 20 minutes.
  • CDI 1.9 g, 12 mmol
  • tetrahydrofuran 40 mL
  • Step 3 tert-butyl (R)-3-(hydroxymethyl)piperazin-1-carboxylate (885 mg, 4.1 mmol) was added to a suspension of 60% sodium hydride (676 mg, 16.9 mmol) in tetrahydrofuran (20 mL) at 0° C. a solution of 5,7-dichloro-1-(4-isopropyl-2-methylpyridin-3-yl)pyridine[2,3-d]pyrimidin-2,4 (1H,3H)-dione (1.49 g, 4.1 mmol) in tetrahydrofuran (20 mL) was dropped thereto. The reaction was stirred at 0° C. for 30 minutes.
  • Step 4 tert-butyl (S)-3-(((7-chloro-1-(4-isopropyl-2-methylpyridin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl)oxy)methylpiperazin-1-formate (1.34 g, 2.45 mmol), diisopropylethylamine (20 mL), dichloromethane (30 mL) were added to a round bottom flask. propylphosphonic anhydride solution (20 mL, 50% w/w ethyl acetate solution was dropped thereto. The reaction was stirred at room temperature for 30 minutes.
  • Steps 5-8 Compound Z92 was prepared according to the method of Example 73.
  • ES-API: [M+H] + 575.2.
  • Step 1 2,4-dichloro-6-fluorobenzoic acid (15 g, 71.4 mmoL) was dissolved in 200 mL of dichloromethane and cooled to 0° C., oxalyl chloride (12 ml, 142.9 mmol) was added. After 30 minutes for the completion of the dropping, DMF (0.5 ml) was dropped, the reaction rised to room temperature and proceeded for 1 hour. After the completion of the reaction, the reaction solution was concentrated and diluted with 150 mL of dichloromethane, cooled to 0° C., slowly dropped to 20 mL of ammonia water, and stirred for 2 hours.
  • Step 2 4,6-dicyclopropylpyrimidin-5-amine (3.56 g, 20.3 mmol) was dissolved in 60 mL of tetrahydrofuran, LiHMDS (38.2 ml, 38.2 mmol) was dropped under the ice water bath under nitrogen protection, stirred for 30 minutes, 2,4,6-nicotinamide (4 g, 19.1 mmol) dissolved in 30 mL of tetrahydrofuran was added to the above reaction solution, slowly rised to room temperature, reacted for 2 hours, cooled under the ice water bath, and dilute hydrochloric acid was dropped to pH of 7-8.
  • Step 3 4,6-dichloro-2-(((4,6-dicyclopropylpyrimidin-5-yl)amino)nicotinamide (6.5 g, 17.9 mmoL) was dissolved in 120 ml of tetrahydrofuran, 60% NaH (3.6 g, 89.5 mmol) was added under the ice water bath, stirred for 15 minutes, then CDI (4.35 g, 26.6 mmol) was added, the reaction proceeded under the ice water bath for 1 hour, raw material disappeared, the reaction solution was poured into ice water, and the pH was adjusted to 7-8 with dilute hydrochloric acid.
  • Step 4 tert-butyl (R)-3-(hydroxymethyl)piperazin-1-carboxylate (2.83 g, 8.48 mmoL) was dissolved in tetrahydrofuran, 60% NaH (1.02 g, 25.4 mm1) was added under the ice water bath, and stirred for 10 minutes. 5,7-dichloro-1-(4,6-dicyclopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2,4(1H, 3H)-dione (4.3 g, 8.48 mmoL) was added, and stirred for 20 minutes.
  • Step 5 tert-butyl (R)-3-((((7-chloro-1-(4,6-dicyclopropylpyrimidin-5-yl)-2,4-dioxo-1,2,3,4-tetrahydropyridine[2,3-d]pyrimidin-5-yl)oxy)methyl)piperazin-1-formate (5.7 g, 10.0 mmoL) was dissolved in dichloromethane, diisopropylethylamine (15.5 g, 120.0 mm1) was added at room temperature, and stirred for 5 minutes. 1-propylphosphonic anhydride (19 g, 30.0 mmoL) was added, stirred for 20 minutes.
  • Step 6 tert-butyl (R)-2-chloro-12-(4,6-dicyclopropylpyrimidin-5-yl)-11-oxo-5a,6,8,9,11,12-hexa hydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7(5H)-carboxylate (550 mg, 1.0 mmoL) was dissolved in 10 mL of acetonitrile, N-chlorosuccinimide (266 mg, 2.0 mmol) was added, heated to 80° C.
  • Step 7 tert-butyl (R)-2,3-dichloro-12-(4,6-dicyclopropylpyrimidin-5-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (180 mg, 0.307 mmoL), (2-fluorophenyl)boronic acid (215 mg, 1.54 mmol), SPhos-Pd-G2 (82 mg, 0.114 mmol) and potassium carbonate (472 mg, 3.42 mmol) was dissolved in 8 mL of dioxane and 2 mL of water, nitrogen was used for replacement, the reaction proceeded at 80° C.
  • Step 8 tert-butyl (R)-3-chloro-12-(4,6-dicyclopropylpyrimidin-5-yl)-2-(2-fluorophenyl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (120 mg, 0.186 mmoL) was dissolved in 10 mL of dichloromethane, 5 mL of trifluoroacetic acid was slowly dropped at room temperature, reacted for 5 hours, then 10 mL of dichloromethane was added.
  • Step 9 (R)-3-chloro-12-(4,6-dicyclopropylpyrimidin-5-yl)-2-(2-fluorophenyl)-5,5a,6,7,8,9-hexahydro-4-oxa-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-11 (12H)-1-one (180 mg, the crude product) was dissolved in dichloromethane, diisopropylethylamine (255 mg, 1.98 mmol) and acrylic anhydride (83 mg, 0.66 mmol) was dropped under the ice water bath, and reacted under the ice bath for 10 minutes.
  • Step 1 4-isopropyl-6-methylpyrimidin-5-amine (2.8 g, 19.1 mmol) and 45 mL of tetrahydrofuran were added to a 250 mL round bottom flask. After the system cooling to 0° C., sodium bis(trimethylsilyl)amide (28.5 mL, 2 M in tetrahydrofuran, 57.3 mmol) was dropped to the reaction solution. After the completion of the dropping, the reaction was stirred at 0° C. for 10 minutes. and then 4,6-dichloro-2-fluoronicotinamide (4 g, 19.1 mmol) in tetrahydrofuran (15 mL) was dropped to the reaction solution.
  • Step 2 4,6-dichloro-2-(((4-isopropyl-6-methylpyrimidin-5-yl)amino)nicotinamide (5.7 g, 16.7 mmol) and 80 mL of dry tetrahydrofuran were added to a 250 mL three-necked round bottom flask, cooled to 0-5° C. under the ice bath, sodium hydride (3 g, 75.1 mmol) was added in batches, and the reaction proceeded at this temperature for 5 minutes. A suspension of CDI (4 g, 24.7 mmol) in tetrahydrofuran (40 mL) was dropped to the above solution, and then the reaction proceeded at this temperature for 10 minutes.
  • CDI 4 g, 24.7 mmol
  • tetrahydrofuran 40 mL
  • Step 3 tert-butyl (R)-3-(hydroxymethyl)piperazin-1-carboxylate (3.2 g, 14.8 mmol) was added to a suspension of 60% sodium hydride (1.5 g, 36.9 mmol) in tetrahydrofuran (60 mL) at 0° C. A solution of 5,7-dichloro-1-(4-isopropyl-6-methylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2,4 (1H,3H)-dione (4.5 g, 12.3 mmol) in tetrahydrofuran (20 mL) was dropped thereto. The reaction was stirred at 0° C. for 30 minutes.
  • Step 4 tert-butyl (R)-3-((((7-chloro-1-(4-isopropyl-6-methylpyrimidin-5-yl)-2,4-dioxo-1,2,3,4-tetrahydropyridinyl[2,3-d]pyrimidin-5-yl)oxy)methylpiperazin-1-formate (3 g, 5.5 mmol), diisopropylethylamine (10 mL), dichloromethane (30 mL) were added to a round bottom flask. 1-propylphosphonic anhydride solution (10 mL, 50% w/w ethyl acetate solution) was dropped thereto. The reaction was stirred at room temperature for 30 minutes.
  • Step 5 tert-butyl (R)-2-chloro-12-(4-isopropyl-6-methylpyrimidin-5-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cycloheptan[1,2,3-de]-naphthalen-7 (5H)-carboxylate (500 mg, 0.9 mmol), N-chlorosuccinimide (252 mg, 1.9 mmol) and acetonitrile (10 mL) were added to a round bottom flask. The reaction was stirred at 80° C. for 2 hours.
  • Step 6 tert-butyl (R)-2,3-dichloro-12-(4-isopropyl-6-methylpyrimidin-5-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (200 mg, 0.36 mmol), 2-fluoro-phenylboronic acid (124 mg, 0.89 mmol), Pd(PPh 3 ) 4 (42 mg, 0.036 mmol), sodium carbonate (114 mg, 1.08 mmol), 18 mL of dioxane and 2 mL of water were added to a 100 mL reaction flask.
  • the reaction was stirred at 80° C. for 2.5 hours under nitrogen protection, and the reaction stopped. 20 mL of water was added to the reaction solution. The reaction solution was extracted with 20 mL of ethyl acetate for 3 times, and the organic phase was dried and concentrated.
  • Step 7 tert-butyl (R)-3-chloro-2-(2-fluorophenyl)-12-(4-isopropyl-6-methylpyrimidin-5-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (170 mg, 0.27 mmol), 1 mL of methanol and 3 mL of hydrogen chloride/dioxane solution (4 M) were added to a round bottom flask. The reaction was stirred at room temperature for 1 hour.
  • Step 8 (R)-3-chloro-2-(2-fluorophenyl)-12-(4-isopropyl-6-methylpyrimidin-5-yl)-5,5a, 6,7,8,9-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cycloheptan[1,2,3-de]-naphthalen-11 (12H)-one (167 mg, 0.32 mmol), 3 mL of dichloromethane and triethylamine (97 mg, 0.96 mmol) were added to a round bottom flask.
  • the reaction was cooled to 0° C., and acrylic anhydride in dichloromethane (40 mg, 0.32 mmol, 0.5 mL) was dropped to the reaction solution.
  • the reaction was stirred at 0° C. for 10 minutes.
  • 40 mL of the saturated sodium bicarbonate aqueous solution was added to the reaction solution, and the reaction solution was extracted with 20 mL of dichloromethane for 3 times.
  • the organic phase was dried and concentrated.
  • the crude product was purified by Preparative HPLC to obtain a racemate Z95.
  • ES-API: [M+H] + 576.2.
  • ES-API: [M+H] + 594.1.
  • Step 1 tert-butyl (R)-2-chloro-12-(4,6-diisopropylpyrimidin-5-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (450 mg, 0.81 mmol) and a solution of N-chlorosuccinimide (216 mg, 1.62 mmol) in acetonitrile (20 mL) was stirred at 80° C. for 2 hours under nitrogen protection.
  • Steps 2-4 Compound Z97 was prepared according to the method of Example 46.
  • Step 1 tert-butyl (R)2-chloro-12-(4,6-dicyclopropylpyrimidin-5-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (2.0 g, 3.63 mmoL) was dissolved in 100 mL of acetonitrile, Selectfluor (6.64 g, 18.2 mmol) was added, heated to 55° C.
  • Steps 2-4 Compound Z99 was prepared according to the method of steps 7-9 in Example 93.
  • ES-API: [M+H] + 600.1.
  • Step 1 tert-butyl (R)-2-chloro-3-fluoro-12-(2-isopropyl-4-methylpyrid-3-yl)-11-oxo-5a,6,8,9,11,12-hexahydro-4-oxo-1,7,9a,10,12-pentazabenzo[4,5]cyclohepta[1,2,3-de]naphthalen-7 (5H)-carboxylate (3.2 g, 5.87 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (5.5 g, 35.25 mmol), SPhos-pd-G2 (1.0 g, 1.1 mmol), potassium phosphate (2.5 g, 11.79 mmol), 100 mL of dioxane and 20 mL of water were added to a 250 mL three-necked round bottom flask.
US17/607,311 2019-04-28 2020-04-28 Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof Pending US20220251109A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910349813.4 2019-04-28
CN201910349813 2019-04-28
PCT/CN2020/087428 WO2020221239A1 (zh) 2019-04-28 2020-04-28 氧杂氮杂喹唑啉-7(8h)-酮类化合物，其制法与医药上的用途

Publications (1)

Publication Number Publication Date
US20220251109A1 true US20220251109A1 (en) 2022-08-11

Family

ID=73029647

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/607,311 Pending US20220251109A1 (en) 2019-04-28 2020-04-28 Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof

Country Status (6)

Country Link
US (1) US20220251109A1 (zh)
EP (1) EP3964516A4 (zh)
JP (1) JP7280975B2 (zh)
KR (1) KR20220012255A (zh)
CN (1) CN113767106B (zh)
WO (1) WO2020221239A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
TW202115089A (zh) * 2019-07-01 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 喹唑啉酮類衍生物、其製備方法及其在醫藥上的應用
CN112300195B (zh) * 2019-08-02 2021-12-24 上海济煜医药科技有限公司 四并环类化合物及其制备方法和应用
CN112390818B (zh) * 2019-08-12 2023-08-22 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
MX2022003537A (es) 2019-09-24 2022-07-11 Mirati Therapeutics Inc Terapias de combinacion.
JP7340100B2 (ja) 2019-10-28 2023-09-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬
KR20220130126A (ko) 2019-12-20 2022-09-26 미라티 테라퓨틱스, 인크. Sos1 억제제
CN113980032B (zh) * 2020-07-27 2023-06-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
CN115461334A (zh) * 2020-11-27 2022-12-09 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
AU2022280025A1 (en) * 2021-05-25 2023-12-07 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
CA3226720A1 (en) * 2021-07-23 2023-01-26 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
WO2023066371A1 (zh) * 2021-10-22 2023-04-27 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2024002024A1 (zh) * 2022-06-27 2024-01-04 石药集团中奇制药技术（石家庄）有限公司 三环类化合物及其用途
WO2024032703A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3356354A1 (en) * 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3621968A1 (en) * 2017-05-11 2020-03-18 Astrazeneca AB Heteroaryl compounds that inhibit g12c mutant ras proteins
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
CN113767106B (zh) 2024-02-20
KR20220012255A (ko) 2022-02-03
JP7280975B2 (ja) 2023-05-24
CN113767106A (zh) 2021-12-07
JP2022531196A (ja) 2022-07-06
EP3964516A4 (en) 2023-01-11
EP3964516A1 (en) 2022-03-09
WO2020221239A1 (zh) 2020-11-05

Similar Documents

Publication Publication Date Title
US20220251109A1 (en) Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof
US20230084095A1 (en) Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
US20220363681A1 (en) Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
US11453683B1 (en) KRas G12D inhibitors
US20230203060A1 (en) Fused tricyclic compound, pharmaceutical composition thereof, and use thereof
WO2020177629A1 (zh) 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
EP4332105A1 (en) Pyridino- or pyrimido-cyclic compound, preparation method therefor and medical use thereof
KR20230157463A (ko) 피리미딘-융합된 환형 화합물, 이의 제조 방법 및 이의 용도
CN112390818A (zh) 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
CN114144230B (zh) 作为eed和prc2调节剂的大环唑并吡啶衍生物
CN112047937B (zh) 四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物，其制法与医药上的用途
WO2013003383A1 (en) Bridged bicyclic compounds for the treatment of bacterial infections
US20220169647A1 (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
US20230192734A1 (en) Tricyclic compounds as egfr inhibitors
EP4303216A1 (en) Fused ring substituted six-membered heterocyclic compound, preparation method therefor and use thereof
KR20200090636A (ko) 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CN114478528A (zh) 芳甲酰取代的三环化合物及其制法和用途
TW202340211A (zh) 嘧啶雜環化合物、其製法與醫藥上的用途
JP7441477B2 (ja) ジヒドロナフチリドン系化合物、その調製方法及び医薬への使用
US20240158417A1 (en) Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
RU2815814C1 (ru) Замещенное гетероциклическое конденсированное циклическое соединение, способ его получения и его фармацевтическое применение
TWI838644B (zh) 芳甲醯取代的三環化合物及其製法和用途
WO2023131122A1 (zh) 稠环取代的六元杂环化合物及其制法和用途

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZHEJIANG GENFLEET THERAPEUTICS CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHOU, FUSHENG;CAI, LIJIAN;JIANG, TAO;AND OTHERS;SIGNING DATES FROM 20210922 TO 20211013;REEL/FRAME:057969/0134

Owner name: GENFLEET THERAPEUTICS (SHANGHAI) INC., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHOU, FUSHENG;CAI, LIJIAN;JIANG, TAO;AND OTHERS;SIGNING DATES FROM 20210922 TO 20211013;REEL/FRAME:057969/0134

AS Assignment

Owner name: ZHEJIANG GENFLEET THERAPEUTICS CO., LTD., CHINA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CITY OF THE SECOND ASSIGNEE PREVIOUSLY RECORDED AT REEL: 057969 FRAME: 0134. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:ZHOU, FUSHENG;CAI, LIJIAN;JIANG, TAO;AND OTHERS;SIGNING DATES FROM 20210922 TO 20211013;REEL/FRAME:059820/0961

Owner name: GENFLEET THERAPEUTICS (SHANGHAI) INC., CHINA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CITY OF THE SECOND ASSIGNEE PREVIOUSLY RECORDED AT REEL: 057969 FRAME: 0134. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:ZHOU, FUSHENG;CAI, LIJIAN;JIANG, TAO;AND OTHERS;SIGNING DATES FROM 20210922 TO 20211013;REEL/FRAME:059820/0961

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION